Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(benzyloxycarbonyl-Phe-Arg)2-R110 + H2O
?
-
rhodamine-labeled substrate
-
-
?
2-aminobenzoic acid-Lys-Leu-Ala-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Ala + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Ala-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Ala-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Arg-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Arg-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Asn-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Asn-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Gln-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Gln-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Glu-Glu-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Glu-Glu-epsilon-amino-caproic acid-Glu-Leu-Lys + Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Glu-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Glu-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Glu-Leu-Lys + Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Gly-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Gly-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-His-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-His-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Ile-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Ile-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Leu-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Leu-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Arg-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Arg-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Asn-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Asn-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Asp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Asp-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Gln-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Gln-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Glu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Glu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Gly-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Gly-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-His-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-His-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Ile-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Ile-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Ala-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
?
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Arg-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Arg-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Asn-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Asn-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Gln-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Gln-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Glu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Glu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Gly-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Gly-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-His-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + His-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ile-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ile-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Leu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Leu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Phe-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Phe-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Pro-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Pro-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ala-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Ala-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Arg-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Arg-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Asn-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Asn-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gln-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Gln-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gly-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Gly-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-His-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-His-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ile-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Ile-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Leu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Leu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Phe-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Phe-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Pro-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Pro-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Val-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Val-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Val-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Val-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Asn-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Asn + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Asp-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Asp + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Gln-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Gln + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Glu-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Glu + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Gly-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Gly + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-His-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-His + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Ile-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Ile + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Lys-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Lys + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Met-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Met + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Phe-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Phe + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Pro-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Pro + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Ser-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Ser + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Thr-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Thr + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Val-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Val + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Lys-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Lys-epsilon-amino-caproic acid-Glu-Leu-Lys + Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Met-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Met-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Phe-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Phe-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Pro-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Pro-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Ser-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Ser-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Thr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Thr-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Trp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Trp-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Tyr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Tyr-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Lys-Val-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Val-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Met-Ile-Ser-Leu-Met-Lys-Arg-Pro-Pro-Gly-Trp-Ser-Pro-Phe-Arg-Ser-Ser-Arg-Ile-Trp-NH2 + H2O
2-aminobenzoyl-Met-Ile-Ser-Leu-Met-Lys + Arg-Pro-Pro-Gly-Trp-Ser-Pro-Phe-Arg + 2-aminobenzoyl-Met-Ile-Ser-Leu-Met + Lys-Arg-Pro-Pro-Gly-Trp-Ser-Pro-Phe-Arg + Ser-Ser-Arg-Ile-Trp-NH2
-
-
-
-
?
2-aminobenzoyl-Phe-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Phe-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
2-aminobenzoyl-Val-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Val-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
-
-
?
3-carboxypropionyl-Ala-Phe-Lys-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
48 kDa intermediate of cathepsin D + H2O
34 kDa mature cathepsin D + ?
-
-
-
-
?
Abz-3-biphenyl-L-Ala-Arg-Ala-Ala-Tyr(3-NO2)-NH2 + H2O
Abz-3-biphenyl-L-Ala-Arg + L-Ala-Ala-3-nitrotyrosineamide
-
-
-
-
?
Abz-3-biphenyl-L-Ala-Arg-Ala-Gln-Tyr(3-NO2)-NH2 + H2O
Abz-3-biphenyl-L-Ala-Arg + L-Ala-Gln-3-nitrotyrosineamide
-
-
-
-
?
Abz-3-biphenyl-L-Ala-Arg-Ala-Ser-Tyr(3-NO2)-NH2 + H2O
Abz-3-biphenyl-L-Ala-Arg + L-Ala-Ser-3-nitrotyrosineamide
-
-
-
-
?
Abz-PR-acetyl-K-QLATKAARKSAK-Dnp + H2O
?
-
-
-
?
Abz-PRKQLAT-acetyl-K-AARKSAK-Dnp + H2O
?
-
-
-
?
Abz-PRKQLATKAAR-dimethyl-K-SAK-Dnp + H2O
?
-
-
-
?
Abz-PRKQLATKAARKSAK-Dnp + H2O
?
-
-
-
?
acetyl-AGPRNAA-N-methyl amide + H2O
acetyl-AGPR + NAA-N-methyl amide
docking study
-
-
?
actomyosin + H2O
?
-
endogenous cathepsin L of red bulleye surimi participates in gel disintegration during kamaboko processing by degrading the myosin heavy chain of actomyosin and consequently hindering the gelation of red bulleye surimi
-
-
?
alpha-casein + H2O
?
-
-
-
?
Arg-4-methylcoumarin 7-amide + H2O
Arg + 7-amino-4-methylcoumarin
BAM-22P + H2O
(Met)enkephalin + ?
-
-
-
-
?
benzoyl-Arg-4-nitroanilide + H2O
benzoyl-Arg + 4-nitroaniline
-
-
-
-
?
benzoyl-L-Phe-L-Val-L-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
benzoyl-Phe-Ala-Arg-4-methoxy-2-naphtylamide + H2O
benzoyl-Phe-Ala-Arg + 4-methoxy-2-naphthylamine
-
-
-
?
benzoyl-Phe-Val-Arg-4-methylcoumarin 7-amide + H2O
?
benzyloxycarbonyl-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-Gly-Gly-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Gly-Gly-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
28.61% activity compared to benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Gly-Pro-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-L-Arg-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Arg-L-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-L-citrulline-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-L-citrulline 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-L-Leu-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Leu-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-L-Leu-L-Leu-L-Glu-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Leu-L-Leu-L-Glu + 7-amino-4-methylcoumarin
76.66% activity compared to benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-4-nitroanilide + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 4-nitroaniline
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-trifluoromethylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-trifluoromethylcoumarin
-
cathepsin L specific synthetic substrate
-
-
?
benzyloxycarbonyl-L-Val-L-Leu-L-Lys-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Val-L-Leu-L-Lys + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Leu-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
benzyloxycarbonyl-Leu-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-Lys-Arg + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Lys-Gln-Lys-Leu-Arg-7-amido-4-methylcoumarin + H2O
?
-
preferred substrate
-
-
?
benzyloxycarbonyl-Lys-p-nitrophenyl ester + H2O
benzyloxycarbonyl-Lys + 4-nitrophenol
-
-
-
-
?
benzyloxycarbonyl-Phe-Ala-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methoxy-beta-naphthylamide + H2O
benzyloxycarbonyl-Phe-Arg + 4-methoxy-beta-naphthylamine
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-Phe-Arg-4-nitroanilide + H2O
?
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-Phe-Val-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin
-
-
-
?
Bovine serum albumin + H2O
?
cathepsin D + H2O
?
-
-
-
-
?
Cbz-Phe-Arg-7-amido-4-methylcoumarin + H2O
Cbz-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
CCAAT-displacement protein/cut homeobox protein + H2O
p90 isoform of CCAAT-displacement protein/cut homeobox protein + p110 isoform of CCAAT-displacement protein/cut homeobox protein + ?
-
-
-
-
?
CCALNNGGGALVPRGSGTAK-(5-carboxyfluorescein)-NH2 + H2O
?
-
-
-
-
?
Cholecystokinin + H2O
?
-
-
-
-
?
chromogranin A + H2O
catestatin
-
-
-
-
?
chromogranin A + H2O
catestatin fragments + ?
-
-
-
-
?
collagen type IV + H2O
?
-
-
-
-
?
collagen XVIII + H2O
endostatin + ?
-
-
-
-
?
CUX1 transcription factor + H2O
?
-
-
-
-
?
CV-(L-Phe-Arg)2 + H2O
?
-
-
-
?
D-Val-Leu-Arg-7-amido-4-methylcoumarin + H2O
D-Val-Leu-Arg + 7-amino-4-methylcoumarin
D-Val-Leu-Lys-7-amido-4-methylcoumarin + H2O
D-Val-Leu-Lys + 7-amino-4-methylcoumarin
-
-
-
-
?
Disrupted in renal carcinoma 2 + H2O
?
-
the substrate is proteolytically processed into a N-glycosylated N-terminal and a non-glycosylated C-terminal fragment, respectively. The cleavage site is between amino acid residues 214 and 261
-
-
?
dynamin + H2O
?
CatL is highly reactive toward recombinant dynamin at pH 5.0 and 6.0
-
-
?
E-cadherin + H2O
?
-
-
-
-
?
endorepellin + H2O
anti-apoptotic C-terminal fragment of endorepellin + ?
epidermal growth factor receptor + H2O
?
-
-
-
-
?
FabA antibody + H2O
?
model protein, determination of fragments compared to the recombinant murine enzyme
-
-
?
Fibrinogen + H2O
?
-
-
-
-
?
GABARAP-II protein + H2O
?
-
-
-
-
?
gamma-globulin + H2O
?
-
-
-
-
?
Glucagon + H2O
?
-
-
-
-
?
glycogen phosphorylase + H2O
?
-
-
-
-
?
H2N-Abz-DLVGDVRLAGV-3-nitroYA-CONH2 + H2O
?
-
-
-
-
?
histone + H2O
?
-
-
-
-
?
histone H1 + H2O
?
-
-
-
-
?
immunoglobulin G + H2O
?
-
-
-
?
insulin + H2O
?
-
-
-
-
?
insulin receptor + H2O
?
-
-
-
-
?
insulin-like growth factor-1 receptor + H2O
?
-
-
-
-
?
interleukin-8 precursor + H2O
?
-
enzyme plays an important role in IL-8 processing in inflammatory sites
-
?
kininogen + H2O
kinin + ?
L-Ala-L-Ala-L-Phe-7-amido-4-methylcoumarin + H2O
L-Ala-L-Ala-L-Phe + 7-amino-4-methylcoumarin
28.66% activity compared to benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
-
?
L-arginine 7-amido-4-methylcoumarin + H2O
?
-
very poor substrate
-
-
?
L-lactate dehydrogenase + H2O
?
-
-
-
-
?
L-Leu-L-Arg-7-amido-4-methylcoumarin + H2O
L-Leu-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Phe-L-Arg + 7-amino-4-methylcoumarin
L-Pro-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Pro-L-Phe-L-Arg + 7-amino-4-methylcoumarin
L-pyroglutamyl-L-Phe-Leu-p-nitroanilide + H2O
L-pyroglutamyl-L-Phe-Leu + p-nitroaniline
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin + H2O
L-Val-L-Leu-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
LC3-II protein + H2O
?
-
-
-
-
?
Leu-Trp-Met-Arg-Phe-Ala + H2O
Leu-Trp-Met + Arg-Phe-Ala
-
-
-
?
Leu-Tyr-7-amido-4-methylcoumarin + H2O
Leu-Tyr + 7-amino-4-methylcoumarin
-
-
-
-
?
methionine enkephalin-Arg-Arg + H2O
?
-
-
-
-
?
methionine enkephalin-Arg-Phe + H2O
?
-
-
-
-
?
myosin heavy chain + H2O
?
N-acetyl-Phe-Arg-7-amido-4-trifluoromethylcoumarin + H2O
N-acetyl-Phe-Arg + 7-amino-4-trifluoromethylcoumarin
-
-
-
-
?
N-benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
N-benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
N-benzyloxycarbonyl-Phe-Arg-2-(4-methoxynaphthylamide) + H2O
N-benzyloxycarbonyl-Phe-Arg + 4-methoxy-2-naphthylamine
-
-
-
-
?
N-benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
N-benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
N-carbobenzoxy-L-arginine-L-arginine 7-amido-4-methylcoumarin + H2O
?
-
7% of the activity with N-carbobenzoxy-L-phenylalanine-L-arginine 7-amido-4-methylcoumarin
-
-
?
N-carbobenzoxy-L-phenylalanine-L-arginine 7-amido-4-methylcoumarin + H2O
?
-
-
-
-
?
N2-benzoyl-L-argininamide + H2O
NH3 + N2-benzoyl-L-arginine
-
-
-
?
Nalpha-benzoyl-L-Arg 2-naphthylamide + H2O
Nalpha-benzoyl-L-Arg + 2-naphthylamine
-
-
-
-
?
Nalpha-benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
Nalpha-benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
Nipah virus fusion protein + H2O
?
phosphorylase a + H2O
?
-
-
-
-
?
precursor form 77IL-8 of interleukin-8 + H2O
precursor form 72IL-8 of interleukin-8 + ?
-
cleavage between Arg5 and Ser6
-
?
pro-dipeptidyl peptidase I
?
pro-dynorphin + H2O
?
-
-
-
-
?
pro-enkephalin + H2O
enkephalin + ?
-
-
-
-
?
pro-neuropeptide Y + H2O
neuropeptide Y + ?
cathepsin L cleaves pro-neuropeptide Y (1-70) to generate neuropeptide Y-Gly (1-38) and the COOH-terminal peptide fragment (39-70)
-
-
?
Pro-opiomelanocortin + H2O
?
-
-
-
-
?
Pro-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
Pro-Phe-Arg-4-methylcoumarin 7-amide + H2O
Pro-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
pro-urokinase plasminogen activator + H2O
?
-
-
-
-
?
procathepsin L + H2O
cathepsin L + ?
autoactivation
-
-
?
proheparanase + H2O
active form of heparanase + ?
secretory leukocyte protease inhibitor + H2O
?
-
incubation of recombinant secretory leukocyte protease inhibitor with cathepsin L leads to complete loss of activity while encapsulation of recombinant secretory leukocyte protease inhibitor in 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine]-cholesterol liposomes retains 92.6% of its activity after challenge with cathepsin L
-
-
?
soluble type I collagen + H2O
?
kinetics of collagen binding to cathepsin L, overview. The enzyme cleaves after residue Gln24, the recognition sequence is Gly-Phe-Gln-/-Gly-Pro-Pro (corresponding to positions P3 to P3')
-
-
?
succinyl-Ala-Phe-Lys-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
succinyl-Ala-Phe-Lys-4-methylcoumarin 7-amide + H2O
succinyl-Ala-Phe-Lys + 7-amino-4-methylcoumarin
-
-
-
-
?
succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin + H2O
succinyl-Leu-Leu-Val-Tyr + 7-amino-4-methylcoumarin
-
-
-
-
?
succinyl-Tyr-Met-2-naphthylamide + H2O
?
-
-
-
-
?
surimi protein + H2O
?
-
-
-
-
?
tert-butoxycarbonyl-Arg-Arg-methylcoumarin 7-amide + H2O
tert-butoxycarbonyl-Arg-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butoxycarbonyl-Arg-Val-Arg-Arg-methylcoumarin 7-amide + H2O
tert-butoxycarbonyl-Arg-Val-Arg-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butoxycarbonyl-Val-Pro-Arg-methylcoumarin 7-amide + H2O
tert-butoxycarbonyl-Val-Pro-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-Gln-Ala-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg + 7-amino-4-methylcoumarin
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys + 7-amino-4-methylcoumarin
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg + 7-amino-4-methylcoumarin
tert-butyloxycarbonyl-Val-Leu-Lys-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
tert-butyloxycarbonyl-Val-Leu-Lys-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-Val-Leu-Lys + 7-amino-4-methylcoumarin
-
1% activity compared to benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
?
thyroglobulin type-1 domain + H2O
?
-
the thyroglobulin type-1 domain is a protein module that occurs in a variety of secreted and membrane proteins and is recognised as a potent inhibitor of cysteine proteases. Nevertheless, at high enzyme and inhibitor concentrations in the mircomolar range cathepsin L degrades thyroglobulin type-1 domain
-
-
?
topoisomerase-IIalpha + H2O
?
-
-
-
-
?
tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tosyl-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
trypsinogen + H2O
trypsin + ?
-
cathepsin L inactivates human trypsinogen, CTSL-induced cleavage of trypsinogen occurs 3 amino acids toward the C-terminus from the cathepsin B activation site and results in a truncated, inactive form of trypsin and an elongated propeptide (trypsinogen activation peptide)
-
-
?
Tyr-Gly-Gly-Phe-Leu + H2O
Tyr-Gly + Gly-Phe-Leu
-
-
-
?
Tyr-Gly-Gly-Phe-Leu-Arg + H2O
Tyr-Gly + Gly-Phe-Leu-Arg
-
-
-
?
Tyr-Gly-Gly-Phe-Leu-Arg-Arg + H2O
Tyr-Gly + Gly-Phe-Leu-Arg-Arg
-
-
-
?
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile + H2O
Tyr-Gly + Gly-Phe-Leu-Arg-Arg-Ile
-
-
-
?
Tyr-Gly-Gly-Phe-Met + H2O
Tyr-Gly + Gly-Phe-Met
-
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Arg + H2O
Tyr-Gly + Gly-Phe-Met-Arg-Arg
Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu + H2O
?
-
cleavage sites Gly-Gly and Met-Arg
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Phe + H2O
?
-
cleavage sites: Gly-Gly and Met-Arg
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Phe-NH2 + H2O
?
-
cleavage sites Gly-Gly and Met-Arg
-
-
?
Tyr-Gly-Gly-Phe-Met-NH2 + H2O
Tyr-Gly + Gly-Phe-Met-NH2
Z-Phe-Arg-7-amido-4-methyl-coumarin + H2O
?
-
5 microM, pH 6.5, 28°C
-
-
?
Z-Phe-Arg-7-amido-4-methylcoumarin + H2O
Z-Phe-Arg + 7-amino-4-methylcoumarin
Z-Val-Val-Arg-AMC + H2O
Z-Val-Val-Arg + 7-amino-4-methylcoumarin
a cathepsin L-specific substrate
-
-
?
Zaire Ebola virus glycoprotein + H2O
?
-
-
three cleavage fragments with masses of 23000, 19000, and 4000 Da. Cleavage removes a glycosylated glycan cap and mucin-like domain (MUC domain) and exposes the conserved core residues implicated in receptor binding
-
?
additional information
?
-
Albumin + H2O
?
-
isoform CatL5 shows weak activity against albumin
-
-
?
Albumin + H2O
?
-
-
-
-
?
Arg-4-methylcoumarin 7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
no activity
-
-
?
Arg-4-methylcoumarin 7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
azocasein + H2O
?
-
-
-
-
?
azocasein + H2O
?
-
-
-
?
azocasein + H2O
?
-
-
-
-
?
azocasein + H2O
?
-
-
-
-
?
azocasein + H2O
?
-
-
-
-
?
azocasein + H2O
?
-
low activity
-
-
?
azocasein + H2O
?
-
-
-
-
?
azocasein + H2O
?
-
-
-
-
?
azocasein + H2O
?
-
-
-
-
?
azocasein + H2O
?
-
-
-
-
?
benzoyl-L-Phe-L-Val-L-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzoyl-L-Phe-L-Val-L-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzoyl-Phe-Val-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzoyl-Phe-Val-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg + 7-amino-4-methylcoumarin
-
7% activity compared to benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
-
no activity
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
-
no activity
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
-
weak activity
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
-
weak activity
-
-
?
benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg-Arg + 7-amino-4-methylcoumarin
-
9% activity compared to benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Gly-Pro-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Gly-Pro-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Gly-Pro-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Arg-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Arg-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Arg-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Arg-L-Arg + 7-amino-4-methylcoumarin
88.77% activity compared to benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-4-nitroanilide + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 4-nitroaniline
-
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-4-nitroanilide + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 4-nitroaniline
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
100% activity
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
100% activity
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
preferred substrate
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
substrate for both cathepsin L and cathepsin B
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
100% activity
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
most efficient substrate
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
substrate for both cathepsin L and cathepsin B
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Bovine serum albumin + H2O
?
-
-
-
?
Bovine serum albumin + H2O
?
-
-
-
?
casein + H2O
?
-
-
-
-
?
Collagen + H2O
?
-
substrate for cathepsin L mutant A205L
-
-
?
Collagen + H2O
?
-
-
-
-
?
Collagen + H2O
?
-
-
-
-
?
Collagen + H2O
?
-
selective cleavage of terminal peptides leads to conversion of beta- and higher components mainly to alpha-chains
-
-
?
Collagen + H2O
?
-
conversion of cross-linked beta-chain dimers into uncross-linked alpha-chain monomers
-
-
?
D-Val-Leu-Arg-7-amido-4-methylcoumarin + H2O
D-Val-Leu-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
D-Val-Leu-Arg-7-amido-4-methylcoumarin + H2O
D-Val-Leu-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Elastin + H2O
?
-
tritiated elastin
-
-
?
Elastin + H2O
?
-
the enzyme shows distinctive preferences in degrading elastins from bovine neck ligament, aorta, and lung
-
-
?
Elastin + H2O
?
-
-
-
-
?
endorepellin + H2O
anti-apoptotic C-terminal fragment of endorepellin + ?
-
recombinant endorepellin is an in vitro substrate. Inhibition of cathepsin L activity in endothelial cells exposed to pro-apoptotic stimuli prevents release of anti-apoptotic C-terminal fragment of endorepellin without modulating the development of apoptosis. Inhibition of caspase-3 activation in endothelial cells concomitantly prevents cathepsin L release, production of anti-apoptotic C-terminal fragment of endorepellin, and the development of paracrine anti-apoptotic activity
-
-
?
endorepellin + H2O
anti-apoptotic C-terminal fragment of endorepellin + ?
-
recombinant endorepellin is an in vitro substrate
-
-
?
fibronectin + H2
?
-
enzyme cleaves fibronectin to produce two bands
-
?
fibronectin + H2
?
-
enzyme cleaves fibronectin to produce two bands
-
?
Fibronectin + H2O
?
-
-
-
?
Fibronectin + H2O
?
-
cleavage occurs only at pH 5.5
-
-
?
Fibronectin + H2O
?
-
cleavage occurs only at pH 5.5
-
-
?
Fibronectin + H2O
?
-
-
-
-
?
Fibronectin + H2O
?
-
-
-
-
?
Gelatin + H2O
?
-
-
-
?
Gelatin + H2O
?
-
-
-
-
?
Gelatin + H2O
?
-
-
-
-
?
Gelatin + H2O
?
on gelatin-zymography, the purified pro-mature enzyme of cathepsin L is capable of hydrolyzing 0.1% gelatin at pH 7.5
-
-
?
Gelatin + H2O
?
-
-
-
-
?
Gelatin + H2O
?
-
-
-
-
?
Gelatin + H2O
?
-
low activity
-
-
?
Gelatin + H2O
?
-
-
-
-
?
Gelatin + H2O
?
-
-
-
-
?
Hemoglobin + H2O
?
-
-
-
?
Hemoglobin + H2O
?
-
-
-
-
?
Hemoglobin + H2O
?
-
-
-
-
?
Hemoglobin + H2O
?
-
-
-
-
?
histone H3 + H2O
?
-
-
-
?
histone H3 + H2O
?
-
during embryonic stem cell differentiation, histone H3 is proteolytically cleaved at its N-terminus. H3 cleavage may be regulated by covalent modifications present on the histone tail itself
-
-
?
Immunoglobulin + H2O
?
-
-
-
-
?
Immunoglobulin + H2O
?
-
-
-
-
?
Insulin B-chain + H2O
?
-
-
-
?
Insulin B-chain + H2O
?
-
preferential cleavage at: Glu13-Ala14, Leu17-Val18, and Tyr26-Thr27
-
-
?
Insulin B-chain + H2O
?
-
main cleavage sites: Glu13-Ala14 and Tyr26-Thr27, minor cleavage sites: Val2-Asn3, Asn3-Gln4, Cys7-Glu8, Tyr16-Leu17, Leu17-Val18
-
-
?
kininogen + H2O
kinin + ?
-
-
-
-
?
kininogen + H2O
kinin + ?
-
high and low molecular weight kininogen
-
?
L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
preferred substrate for isoform CatL5
-
-
?
L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Pro-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Pro-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Pro-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Pro-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-pyroglutamyl-L-Phe-Leu-p-nitroanilide + H2O
L-pyroglutamyl-L-Phe-Leu + p-nitroaniline
-
-
-
-
?
L-pyroglutamyl-L-Phe-Leu-p-nitroanilide + H2O
L-pyroglutamyl-L-Phe-Leu + p-nitroaniline
-
-
-
-
?
laminin + H2
?
-
-
-
?
Laminin + H2O
?
-
-
-
?
Laminin + H2O
?
-
cleavage occurs only at pH 5.5
-
-
?
Laminin + H2O
?
-
cleavage occurs only at pH 5.5
-
-
?
Laminin + H2O
?
-
-
-
-
?
myosin heavy chain + H2O
?
-
-
-
-
?
myosin heavy chain + H2O
?
-
-
-
-
?
Nipah virus fusion protein + H2O
?
-
proteolytically processed within endosomes by cathepsin L
-
-
?
Nipah virus fusion protein + H2O
?
-
cathepsin L specifically converts Nipah virus fusion protein to a mature and fusogenic form
-
-
?
perforin + H2O
?
-
CatL preferentially cleaves a site on full-length recombinant perforin close to its C terminus
-
-
?
perforin + H2O
?
-
CatL preferentially cleaves a site on full-length recombinant perforin close to its C terminus
-
-
?
pro-dipeptidyl peptidase I
?
-
cleavage at K133
-
?
pro-dipeptidyl peptidase I
?
-
cathepsin L could be an important activator of dipeptidyl peptidase I in vivo
-
?
proheparanase + H2O
active form of heparanase + ?
-
removal of the linker peptide and conversion of proheparanase into its active 8 + 50-kDa form is brought about predominantly by cathepsin L. Excision of a 10-amino acid peptide located at the C terminus of the linker segment between two functional cathepsin L cleavage sites at Y156Q and Y146Q is critical for activation of proheparanase. The entire linker segment of proheparanase is susceptible to multiple endocleavages by cathepsin L, generating small peptides. Processing and activation of proheparanase can be brought about solely by cathepsin L
-
-
?
proheparanase + H2O
active form of heparanase + ?
-
removal of the linker peptide and conversion of proheparanase into its active 850-kDa form is brought about predominantly by cathepsin L. Excision of a 10-amino acid peptide located at the C terminus of the linker segment between two functional cathepsin L cleavage sites at Y156Q and Y146Q is critical for activation of proheparanase. The entire linker segment of proheparanase is susceptible to multiple endocleavages by cathepsin L, generating small peptides. Processing and activation of proheparanase can be brought about solely by cathepsin L
-
-
?
serum albumin + H2O
?
-
-
-
?
serum albumin + H2O
?
-
-
-
-
?
serum albumin + H2O
?
-
-
-
-
?
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tosyl-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
-
preferred substrate for isoform CatL1G
-
-
?
tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tosyl-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tosyl-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
type 1 collagen + H2O
?
-
isoform Catl1G completely digests collagen type 1
-
-
?
type 1 collagen + H2O
?
-
efficient cleavage of type 1 collagen by isoform CatL5 is limited to the beta-and gamma-chains
-
-
?
Type I collagen + H2O
?
-
-
-
?
Type I collagen + H2O
?
-
-
-
-
?
Type I collagen + H2O
?
-
-
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Arg + H2O
Tyr-Gly + Gly-Phe-Met-Arg-Arg
-
-
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Arg + H2O
Tyr-Gly + Gly-Phe-Met-Arg-Arg
-
-
-
?
Tyr-Gly-Gly-Phe-Met-NH2 + H2O
Tyr-Gly + Gly-Phe-Met-NH2
-
-
-
-
?
Tyr-Gly-Gly-Phe-Met-NH2 + H2O
Tyr-Gly + Gly-Phe-Met-NH2
-
-
-
?
vitronectin + H2
?
-
-
-
?
vitronectin + H2
?
-
-
-
?
Z-Phe-Arg-7-amido-4-methylcoumarin + H2O
Z-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Z-Phe-Arg-7-amido-4-methylcoumarin + H2O
Z-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
Z-Phe-Arg-7-amido-4-methylcoumarin + H2O
Z-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
additional information
?
-
-
enzyme may involve in invasion of cercaria into fish and development to metacercaria, excystment of metacercaria, and protein digestion of adult
-
-
?
additional information
?
-
no activity with benzyloxycarbonyl-L-Arg-L-Arg-7-amido-4-methylcoumarin. The recombinant CsCPL-m can degrade bovine serum albumin and gelatin, but can not degrade human hemoglobin and human immunoglobulin G
-
-
?
additional information
?
-
-
no activity with benzyloxycarbonyl-L-Arg-L-Arg-7-amido-4-methylcoumarin. The recombinant CsCPL-m can degrade bovine serum albumin and gelatin, but can not degrade human hemoglobin and human immunoglobulin G
-
-
?
additional information
?
-
proteolytic activity only under reducing conditions, e.g. in presence of dithiothreitol. No substrate: type IV collagen
-
-
?
additional information
?
-
-
proteolytic activity only under reducing conditions, e.g. in presence of dithiothreitol. No substrate: type IV collagen
-
-
?
additional information
?
-
proteolytic activity only under reducing conditions, e.g. in presence of dithiothreitol. No substrate: type IV collagen
-
-
?
additional information
?
-
owing to its low specificity, cathepsin L is able to cleave a diversity of proteins, it cleaves a variety of recombinant proteins including monoclonal antibodies, antibody fragments, bispecific antibodies, and fusion proteins. Cathepsin L is a low specificity protease. CHO cathepsin L seems to have preferential cleavage sites on mAbs of different subclass as similar fragment profiles exist for three tested mAbs. IgG1 does not interact with cathepsin L
-
-
?
additional information
?
-
-
owing to its low specificity, cathepsin L is able to cleave a diversity of proteins, it cleaves a variety of recombinant proteins including monoclonal antibodies, antibody fragments, bispecific antibodies, and fusion proteins. Cathepsin L is a low specificity protease. CHO cathepsin L seems to have preferential cleavage sites on mAbs of different subclass as similar fragment profiles exist for three tested mAbs. IgG1 does not interact with cathepsin L
-
-
?
additional information
?
-
-
enzyme activity plays a pivotal role in prolactin-induced spermatogonial apoptosis
-
?
additional information
?
-
-
3% with benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin and 1% with both L-Arg-7-amido-4-methylcoumarin and Boc-Phe-Ser-Arg-7-amido-4-methylcoumarin. No activity with Boc-Gln-Arg-Arg-7-amido-4-methylcoumarin and succinyl-Leu-Leu-Tyr-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
-
the cathepsin B and H specific synthetic substrates benzyloxycarbonyl-L-Ala-L-Ala-7-amido-4-trifluoromethylcoumarin and L-Arg-7-amido-4-methylcoumarin do not show any hydrolysis with the partially purified enzyme
-
-
?
additional information
?
-
-
isoform CatL1G can cleave substrates with proline residues at P2, isoform CatL1G is unable to digest albumin or hemoglobin, efficiently at either pH 5.5 or 7.0
-
-
?
additional information
?
-
-
isoform CatL1G can cleave substrates with proline residues at P2
-
-
?
additional information
?
-
analysis of substrate specificity of FhCL3, strong preference of the cathepsin for Pro and Gly residues at P2 and P3 sites, respectively, of substrates. Residues residues, Q19, G23, G25, W26, G67, W69, Y143, T161, H162 and W184, of FhCL3 largely contribute to the substrate binding. W69, Y143 and T161 have the largest per-residue free energy contributions to the complex formation, interaction analysis, overview
-
-
?
additional information
?
-
-
analysis of substrate specificity of FhCL3, strong preference of the cathepsin for Pro and Gly residues at P2 and P3 sites, respectively, of substrates. Residues residues, Q19, G23, G25, W26, G67, W69, Y143, T161, H162 and W184, of FhCL3 largely contribute to the substrate binding. W69, Y143 and T161 have the largest per-residue free energy contributions to the complex formation, interaction analysis, overview
-
-
?
additional information
?
-
the enzyme performs autocleavage of its proform
-
-
?
additional information
?
-
the enzyme performs autocleavage of its proform
-
-
?
additional information
?
-
-
the enzyme performs autocleavage of its proform
-
-
?
additional information
?
-
-
no activity with benzyloxycarbonyl-Phe-Ala-4-methylcoumarin 7-amide and with benzyloxycarbonyl-Phe-Met-4-methylcoumarin 7-amide
-
-
?
additional information
?
-
-
the enzyme is involved in tissue destruction in arthritis
-
-
?
additional information
?
-
-
the enzyme plays a crucial role in the degradation of the invariant chain during maturation of major histocompatibility complex class II molecules and antigen processing
-
-
?
additional information
?
-
-
differentiation of human macrophages within the lung is accompanied by synthesis and expression of cathepsin L
-
-
?
additional information
?
-
-
CAT L plays a significant role in numerous important physiological and pathological processes, such as bone resorption, cancer progression and atherosclerosis
-
-
?
additional information
?
-
-
cathepsin L has a pro-survival function within the cell which may be due, at least in part, to its ability to deplete the cells from the proapoptotic molecule caspase-3. The existence of a proteolytic hierarchy between pro-survival and pro-death proteases suggests that changes in cellular proteolytic profiles are likely to have significant consequences not only on its survival but also on the type of death it may undergo in response to a specific stress
-
-
?
additional information
?
-
catL is essential for epidermal homeostasis and regular hair follicle morphogenesis and cycling
-
-
?
additional information
?
-
-
contributions of cathepsin L and cathepsin B to autophagic protein degradation of cytoplasmic proteins in HeLa and Huh-7 cells are nearly equal. Cathepsin L does not play a general role in the degradation of proteins in the lumen of autophagosomes, but rather is involved specifically in the degradation of autophagosomal membrane markers
-
-
?
additional information
?
-
-
pituitary gland may utilize the cathepsin L and prohormone convertase pathways for producing propiomelanocortin-derived peptide hormones
-
-
?
additional information
?
-
-
the enzyme does not hydrolyze ortho-aminobenzoic acid-VLFEKKVYLQ-N-[2,4-dinitrophenyl]ethylenediamine, ortho-aminobenzoic acid-KPVSTEQLAQ-N-[2,4-dinitrophenyl]ethylenediamine , Ortho-aminobenzoic acid-KPPVVLLPDQ-N-[2,4-dinitrophenyl]ethylenediamine, ortho-aminobenzoic acid-LFEKQ-N-[2,4-dinitrophenyl]ethylenediamine, ortho-aminobenzoic acid-VLFEKQ-N-[2,4-dinitrophenyl]ethylenediamine, and ortho-aminobenzoic acid-VLFEKKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
?
additional information
?
-
human cathepsin L shows no proline specificity, but collagenolytic activity. Cathepsin L also is a strong gelatinase. Comparison with cathepsin K, overview
-
-
?
additional information
?
-
-
human cathepsin L shows no proline specificity, but collagenolytic activity. Cathepsin L also is a strong gelatinase. Comparison with cathepsin K, overview
-
-
?
additional information
?
-
the enzyme binds to concanavalin A, but not to Lens culinaris agglutinin, Ricinus communis agglutinin 120 (RCA120), and wheat germ agglutinin
-
-
?
additional information
?
-
-
the enzyme binds to concanavalin A, but not to Lens culinaris agglutinin, Ricinus communis agglutinin 120 (RCA120), and wheat germ agglutinin
-
-
?
additional information
?
-
the enzyme performs autocatalytic cleavage
-
-
?
additional information
?
-
no activity towards benzyloxycarbonyl-Gly-Gly-L-Arg-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
-
p4165aa, a 65 amino acid segment of the p41 splice variant of major histocompatibility complex class II-associated invariant chain, stabilizes cathepsin L in the extracellular environment and induces a local decrease in the concentration of matrix-degrading enzymes during inflammation. Through its interaction with cathepsin L, complex class II-associated invariant chain Ii may control the migratory response of antigen-presenting cells and/or the recruitment of effectors of the inflammatory response
-
?
additional information
?
-
upon interferon-gamma activation of peritoneal macrophages, enzymatic activityof cathepsin L is specifically inhibited, such that cathepsin S mediates Ii degradation and regulates MHC class II maturation
-
?
additional information
?
-
-
cathepsin L elevates alpha-secretase activity, thereby suppressing amyloid precursor protein Abeta42 level. Cathepsin L reduces the formation of Abeta42 peptides by cleaving amyloid precursor protein within the Abeta peptide sequence. In addition, both cathepsins B and L degrade Abeta42 into less toxic Abeta peptides
-
-
?
additional information
?
-
-
cathepsin L expression levels regulate cell responsiveness to IGF-type I, function for cathepsin L in the control of the tumorigenic/metastatic phenotype
-
-
?
additional information
?
-
-
cathepsin L has a prominent role in the production of adrenocorticotropic hormone, beta-endorphin, and alpha-melanocyte stimulating hormone
-
-
?
additional information
?
-
cathepsin L has a prominent role in the production of adrenocorticotropic hormone, beta-endorphin, and alpha-melanocyte stimulating hormone
-
-
?
additional information
?
-
-
the enzyme has a preference for hydrophobic amino acids in P2 and P3 residues
-
-
?
additional information
?
-
-
the enzyme removes the Ca-sensitivity of ATPase activity of myofibrils
-
-
?
additional information
?
-
-
involved in extracellular food digestion
-
-
?
additional information
?
-
the recombinant enzyme is inefficient in hydrolyzing azocasein, fibrinogen, and bovine serum albumin
-
-
?
additional information
?
-
-
the enzyme plays a most important role in intralysosomal proteolysis in hepatocytes
-
-
?
additional information
?
-
-
plays a crucial role in the pathogenesis of adjuvant arthritis
-
-
?
additional information
?
-
-
basement membrane of larval brains contains two substrate proteins
-
?
additional information
?
-
-
the enzyme is suggested to play a crucial role in the degradation of the basement membranes
-
?
additional information
?
-
no activity with human immunoglobulin
-
-
?
additional information
?
-
-
no activity with human immunoglobulin
-
-
?
additional information
?
-
-
enzyme has a role in the progress of the cell cycle during the cleavage divisions of embryonic development. Inhibition of the protease abolishes the chromatin decondensation after mitosis
-
-
?
additional information
?
-
granular amoebocytes immunopositive for cathepsin L are chemoattracted to the site of injury and phagocyte bacteria
-
-
?
additional information
?
-
-
granular amoebocytes immunopositive for cathepsin L are chemoattracted to the site of injury and phagocyte bacteria
-
-
?
additional information
?
-
-
leucine is preferred over phenylalanine in position P2
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(((2S,3S)-epoxysuccinyl-(S)-leucyl)amino)-4-guanidinobutane
-
-
(13alpha,17alpha,20S,24Z)-3-hydroxylanosta-7,24-dien-26-oic acid
-
competitive inhibition
(13alpha,17alpha,20S,24Z)-3-oxolanosta-7,24-dien-26-oic acid
-
competitive inhibition
(2-fluorobenzophenone) thiosemicarbazone
-
(2E)-1,3-diphenylprop-2-en-1-one
33% inhibition of FhCL1; 4% inhibition of FhCL3
(2E)-1-(2-hydroxyphenyl)-3-(3-nitrophenyl)prop-2-en-1-one
26% inhibition of FhCL1; 37% inhibition of FhCL3
(2E)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
3% inhibition of FhCL3; 48% inhibition of FhCL1
(2E)-1-(2-hydroxyphenyl)-3-(4-phenoxyphenyl)prop-2-en-1-one
16% inhibition of FhCL3; 8% inhibition of FhCL1
(2E)-1-(2-hydroxyphenyl)-3-(pyridin-2-yl)prop-2-en-1-one
20% inhibition of FhCL19; 54% inhibition of FhCL1
(2E)-1-(2-hydroxyphenyl)-3-(thiophen-2-yl)prop-2-en-1-one
52% inhibition of FhCL1; 9% inhibition of FhCL3
(2E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one
16% inhibition of FhCL2
(2E)-1-(2-hydroxyphenyl)-3-[4-(methylsulfanyl)phenyl]prop-2-en-1-one
19% inhibition of FhCL3
(2E)-1-(7-hydroxynaphthalen-1-yl)-3-(naphthalen-1-yl)prop-2-en-1-one
a slow-reversible inhibitor that interacts with the Cys-His catalytic dyad and key S2 and S3 pocket residues, causing 65% inhibition of FhCL3, enzyme binding structure by molecular docking, overview. Analysis of fasciolicide activity of C34 on vitro cultu; a slow-reversible inhibitor that interacts with the Cys-His catalytic dyad and key S2 and S3 pocket residues, causing 75% inhibition of FhCL1, enzyme binding structure by molecular docking, overview. Analysis of fasciolicide activity of C34 on vitro cultu
(2E)-1-(7-hydroxynaphthalen-1-yl)-3-(naphthalen-2-yl)prop-2-en-1-one
44% inhibition of FhCL3; 67% inhibition of FhCL1
(2E)-1-(8-hydroxynaphthalen-2-yl)-3-(naphthalen-2-yl)prop-2-en-1-one
29% inhibition of FhCL3; 65% inhibition of FhCL1
(2E)-1-(naphthalen-2-yl)-3-phenylprop-2-en-1-one
13% inhibition of FhCL3; 65% inhibition of FhCL1
(2E)-1-phenyl-3-(pyridin-2-yl)prop-2-en-1-one
4% inhibition of FhCL3; 8% inhibition of FhCL1
(2E)-2-(6-bromo-1,1-dioxido-2,3-dihydro-4H-thiochromen-4-ylidene)hydrazinecarbothioamide
-
(2E)-2-(6-bromo-2,3-dihydro-4H-thiochromen-4-ylidene)hydrazinecarbothioamide
-
(2E)-2-(6-bromo-2,3-dihydroquinolin-4(1H)-ylidene)hydrazinecarbothioamide
-
(2E)-2-(6-nitro-2,3-dihydro-4H-thiochromen-4-ylidene)hydrazinecarbothioamide
-
(2E)-2-(7-bromo-3,4-dihydronaphthalen-1(2H)-ylidene)hydrazinecarbothioamide
-
-
(2E)-2-[(2-fluorophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3,4,5-trifluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3,5-dichlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3,5-difluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)[3-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[6-(propan-2-yloxy)-2,3-dihydro-4H-thiochromen-4-ylidene]hydrazinecarbothioamide
-
(2E)-2-[[3,5-bis(trifluoromethyl)phenyl](3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one
11% inhibition of FhCL1; 19% inhibition of FhCL3
(2E)-3-(2-bromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
29% inhibition of FhCL1; 33% inhibition of FhCL3
(2E)-3-(3,4-dimethoxyphenyl)-1-phenylprop-2-en-1-one
2% inhibition of FhCL3; 35% inhibition of FhCL1
(2E)-3-(4-aminophenyl)-1-phenylprop-2-en-1-one
2% inhibition of FhCL3; 4% inhibition of FhCL1
(2E)-3-(4-bromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
12% inhibition of FhCL3; 19% inhibition of FhCL1
(2E)-3-(4-bromophenyl)-1-phenylprop-2-en-1-one
12% inhibition of FhCL3; 52% inhibition of FhCL1
(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
23% inhibition of FhCL3; 63% inhibition of FhCL1
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
25% inhibition of FhCL1; 6% inhibition of FhCL43
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
48% inhibition of FhCL1; 4% inhibition of FhCL3
(2E)-3-(furan-2-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one
4% inhibition of FhCL3; 57% inhibition of FhCL1
(2E)-3-(naphthalen-1-yl)-1-phenylprop-2-en-1-one
17% inhibition of FhCL1; 27% inhibition of FhCL3
(2E)-3-[4-(dimethylamino)phenyl]-1-(2-hydroxyphenyl)prop-2-en-1-one
20% inhibition of FhCL3; 34% inhibition of FhCL1
(2E)-3-[4-(methylsulfanyl)phenyl]-1-phenylprop-2-en-1-one
26% inhibition of FhCL3; 8% inhibition of FhCL1
(2E)-N'-(2-[(naphthalen-1-ylmethyl)sulfanyl]acetyl)-3-phenylprop-2-enehydrazide
-
(2E)-[(3E)-28-methoxy-28-oxours-12-en-3-ylidene]acetic acid
-
competitive inhibition
(2R,3R)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-3-([(2S)-1-[(8-carbamimidamidooctyl)amino]-4-methyl-1-oxopentan-2-yl]carbamoyl)oxirane-2-carboxylic acid
-
-
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(R)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(S)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[biotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(R)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-prolyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R+S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-pipecolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
(2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester
0.1 mM
(2S,3S+2R,3R)-dibenzyl-1-[desthiobiotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
(2Z)-1-[(12R)-22-amino-12-[(1S)-2-(4-benzoylphenyl)-1-[[(benzyloxy)carbonyl]amino]ethyl]-6,13,22-trioxo-17,20-dioxa-7,14-diazadocos-1-yl]-2-[(2E)-3-(1-ethyl-3,3-dimethyl-5-sulfo-2,3-dihydro-1H-indol-2-yl)prop-2-en-1-ylidene]-3,3-dimethyl-2,3-dihydro-1H-indole-5-sulfonic acid
-
(2Z)-2-[(2-bromophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(2-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(2-fluorophenyl)(phenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromo-2-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromo-4-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2,3,4,5-tetrafluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2,3-difluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2,6-difluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(4-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[[3,5-bis(trifluoromethyl)phenyl](4-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(3-bromo-2'-fluoro-3'-hydroxybenzophenone) thiosemicarbazone
-
(3-bromo-3'-hydroxybenzophenone) thiosemicarbazone
a slowly reversible inhibitor of cathepsin L
(3-hydroxybenzophenone) thiosemicarbazone
-
(3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetic acid
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
(3E)-3-(carboxymethylidene)olean-12-en-28-oic acid
-
competitive inhibition
(3E)-3-(carboxymethylidene)urs-12-en-28-oic acid
-
competitive inhibition
(4-bromo-2'-fluoro-3'-hydroxybenzophenone) thiosemicarbazone
-
(E)N-[(S)1-[(S)2-cyano-1-pyrrolidinecarbonyl]-3-methylbutyl]-2,3-diphenylacrylamide
-
selective towards cathepsin L over cathepsin B
(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucine(3-methylbutyl)-amide
-
0.01 mg/ml
(L-3-trans-propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester
-
CA-074Me, more than 99% inhibition at 0.1 mM
(N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide)
(R)-S-2-(2-ethylphenylamino)-2-oxoethyl 2-(2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoyl)hydrazinecarbothioate
R-enantiomer, thiol ester containing a diacyl hydrazine functionality and one stereogenic center
(S)-2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl 2-(2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoyl)hydrazinecarboxylate
-
(S)-S-2-(2-ethylphenylamino)-2-oxoethyl 2-(2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoyl)hydrazinecarbothioate
S-enantiomer, thiol ester containing a diacyl hydrazine functionality and one stereogenic center
1,3,5-trisbenzoylbenzene thiosemicarbazone
-
1,3-bis(2-fluorobenzoyl)-5-bromobenzene thiosemicarbazone
molecular docking in the active site
1,3-bis(3-bromobenzoyl)-5-bromobenzene thiosemicarbazone
-
1,3-bis(3-bromobenzoyl)-5-hydroxybenzene thiosemicarbazone
-
1,3-bis(3-hydroxybenzoyl)-5-bromobenzene thiosemicarbazone
-
1,3-bis(3-methylbenzoyl)benzene thisosemicarbazone
-
1,3-bis(4-bromobenzoyl)benzene bis-thiosemicarbazone
-
1,3-bis(4-bromobenzoyl)benzene thiosemicarbazone
-
1,3-bis(4-fluorobenzoyl)benzene thiosemicarbazone
-
1,3-bis(4-hydroxybenzoyl)benzene thiosemicarbazone
-
1,3-bis(4-isopropoxybenzoyl)benzene thiosemicarbazone
-
1,3-bis(4-methoxybenzoyl)benzene thiosemicarbazone
-
1,3-dihydro-pyrrolo[3,4-b]quinoline-2-carbonitrile
-
IC50: 0.00045 mM
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([2-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-3-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-4-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(thiophen-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[methyl(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(methylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(phenylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-([[4-([[(dimethylamino)methyl]sulfonyl]amino)phenyl]carbonyl]amino)-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([2-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-fluoro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([4-[(ethylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-(methylsulfamoyl)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-([[4-(1-methylethyl)-1,3-thiazol-2-yl]sulfonyl]amino)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-sulfamoylphenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methyl-1H-imidazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methylethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2,2,2-trifluoroethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2-methylphenyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methylpyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(5-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[4-methyl-N-(thiophen-3-ylcarbonyl)-L-leucyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([4-[(benzylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([4-[(butylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([4-[(cyclopropylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-chloropyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(3-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(4-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(cyclohexylmethyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1- (L-trans-epoxysuccinyl-leucylamino)-4-guanidinobutane
-
i.e. E-64, 0.1 mM, complete loss of activity
1-cyano-3-azetidinyl cyclohexylmethyl ether
-
IC50: 0.00001 mM
1-cyanoazetidine
-
IC50: 0.00043 mM
1-cyanopyrrolidine
-
IC50: 0.004 mM
1-hydroxy-6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]-2,1,3-benzoxadiazol-1-ium
21% inhibition of FhCL1; 26% inhibition of FhCL3
1-N-[3,5-bis (trifluoromethyl) phenyl]-2-N-(1-ethynylcyclohexyl) benzene-1,2-dicarboxamide
-
1-naphthalenesulfonyl-Ile-Trp-aldehyde
1-naphthalenesulfonyl-Ile-Trp-CHO
-
reversible inhibitor of cathepsin L
1-nathalenesulfonyl-Ile-Trp-CHO
-
treatment of cells results in suppression of cellular proliferation and the induction of a cell death with no detecable caspase-3 activation or DNA fragmentation. Cell death is associated with increased accumulation of cathepsin D, cellular vacuolization, expression of the mannose 6-phosphate recepto, and the autophagy marker LC-II
1-[(1E)-3-phenylprop-1-en-1-yl]naphthalene
38% inhibition of FhCL1; 39% inhibition of FhCL3
2,3,7,8-tetrachlorodibenzodioxin
-
treatment of cells results in resistance to apoptosis, increased expression of the tumor marker cathepsin L, and a high degree of invasiveness
2,6-dimethoxy-4-[4-(4-phenoxyphenyl)-5-phenyl-1H-imidazol-2-yl]phenol
2,6-dimethoxy-4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
2-(1,3-benzodioxol-5-yl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarboxylate
-
unreactive to transesterification by cysteine and dithiothreitol nucleophiles. Inhibitor remains intact for greater than 24 h when incubated with cathepsin L under stoichiometric conditions, and in the presence of assay buffer
2-(3,4-dimethoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
2-(4-bromophenyl)-4H-chromen-4-one
19% inhibition of FhCL3; 21% inhibition of FhCL1
2-(4-chlorophenyl)-4H-chromen-4-one
17% inhibition of FhCL3
2-(4-methoxyphenyl)-4-[8-[2-(4-methoxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
2-(4-methoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
2-(acetylamino)-N-[4-(6-[[2-(acetylamino)benzoyl]amino]-1H-benzimidazol-2-yl)phenyl]benzamide
2-(furan-2-yl)-4-[8-[2-(furan-2-yl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
2-([4-benzyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl)-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one
-
2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-4-(cyclohexylamino)-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-(cyclohexylmethoxy)-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[(1,4-dioxaspiro[4.5]dec-8-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
2-cyano-4-[(2-cyclopentylethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
2-cyano-4-[(6,8-dioxaspiro[3.5]non-7-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
2-cyano-4-[(cyclohexylmethyl)(methyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[(cyclohexylmethyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-N-(2-phenylethyl)-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-4-[[(4,4-difluorocyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[[(4,4-dimethylcyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[[1-(2-hydroxyethyl)piperidin-4-yl]methoxy]-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-(1-methyl-4-phenylpiperidin-4-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-(2-phenylethyl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-(4,5-dimethoxybiphenyl-2-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-(piperidin-4-ylmethoxy)-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[4.5]dec-8-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[(spiro[3.5]non-7-ylmethyl)amino]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[[1-(1-methylethyl)piperidin-4-yl]methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-[(1-methyl-4-phenylpiperidin-4-yl)methyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-[(1R)-2-pyridin-2-yl-1-(pyrrolidin-1-ylmethyl)ethyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-[5-[(1-methylpiperidin-4-yl)oxy]biphenyl-2-yl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-furancarbonyl-leucyl-leucyl-leucinal
-
-
2-hydroxy-4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]-1,2,5-oxadiazol-2-ium
14% inhibition of FhCL3; 48% inhibition of FhCL1
2-mercaptoethanol
-
50% activity at 2 mM
2-phenyl-4H-chromen-4-one
5% inhibition of FhCL1; 8% inhibition of FhCL3
2-[(1E)-3-phenylprop-1-en-1-yl]naphthalene
38% inhibition of FhCL3; 62% inhibition of FhCL1
2-[(2E)-3-(naphthalen-1-yl)prop-2-en-1-yl]phenol
32% inhibition of FhCL3; 42% inhibition of FhCL1
2-[(2E)-3-(naphthalen-2-yl)prop-2-en-1-yl]phenol
41% inhibition of FhCL3; 61% inhibition of FhCL1
2-[bis(3-bromophenyl)methylidene]-N-ethylhydrazinecarbothioamide
-
-
2-[bis(3-bromophenyl)methylidene]-N-phenylhydrazinecarbothioamide
-
-
2-[bis(3-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
2-[bis(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
2-[bis(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
2-[cyclohexyl(methyl)amino]-4H-3,1-benzothiazin-4-one
-
selective towards cathepsin L over cathepsin G, chymotrypsin, trypsin, human angiotensin-converting enzyme, human leukocyte elastase, acetylcholinesterase
2RS,3RS)-2-benzyl-3-ethyl-1-[N-(benzyloxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
3-(benzyloxy)-1-cyanoazetidine
-
IC50: 0.00001 mM
3-(hydroxyimino)masticadienoic acid
-
competitive inhibition
3-(hydroxyimino)oleanolic acid
-
competitive inhibition
3-benzoylbenzhydrol thiosemicarbazone
-
3-chloro-N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]benzamide
-
pH and temperature not specified in the publication
3-epiursolic acid
-
competitive inhibition
3-hydroxyolean-12-en-28-oic acid
-
competitive inhibition
3-hydroxyurs-12-en-28-oic acid
-
competitive inhibition
3-oxo-urs-12-en-28-oic acid
noncompetitive inhibitor
3-oxoolean-12-en-28-oic acid
-
competitive inhibition
3-oxours-12-en-28-oic acid
-
competitive inhibition
3-[(benzyloxy)methyl]-1-cyanopyrrolidine
-
IC50: 0.00015 mM
3-[(E)-(4-[[4-([2-[([[3-cyclohexyl-N-(morpholin-4-ylcarbonyl)-L-alanyl]amino][(6-[(2Z)-2-[(2E,4E,6Z)-7-(1-ethyl-3,3-dimethyl-5-sulfo-2,3-dihydro-1H-indol-2-yl)hepta-2,4,6-trien-1-ylidene]-3,3-dimethyl-5-sulfo-2,3-dihydro-1H-indol-1-yl]hexanoyl)amino]acetyl)amino]ethyl]amino)-4-oxobutyl](methyl)amino]phenyl)diazenyl]-7-(diethylamino)-5-phenylphenazin-5-ium
-
3-[[(2S)-2-[([3-acetyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
3-[[(2S)-2-[[(4-[[(4-aminophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
4,4'-[methanediylbis(1H-benzimidazole-5,2-diyl)]dianiline
4-(2,5-dimethyl-1H-pyrrol-1-yl)-N'-(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)benzohydrazide
-
4-(4-[8-[2-(4-carboxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)benzoic acid
4-(4-[8-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)phenol
4-amino-N-(4-[6-[(4-aminobenzoyl)amino]-1H-benzimidazol-2-yl]phenyl)benzamide
4-bromophenyl (1E,3S)-3-([N-[(benzyloxy)carbonyl]-L-phenylalanyl]amino)-5-methylhex-1-ene-1-sulfonate
i.e. KD-1
4-bromophenyl (S,E)-3-((S)-2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanamido)-5-methylhex-1-ene-1-sulfonate
i.e. KDP-1, in vivo inhibition of cathepsin L. Inhibition of cathepsin L compared to other cathepsins, overview
4-[(1-acetylpiperidin-4-yl)methoxy]-2-cyano-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
4-[(E)-benzylideneamino]-N-[4-[6-([4-[(E)-benzylideneamino]benzoyl]amino)-1H-benzimidazol-2-yl]phenyl]benzamide
4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
-
4-[4-(5,5-dioxidodibenzo[b,d]thiophen-2-yl)-5-phenyl-1H-imidazol-2-yl]-2,6-dimethoxyphenol
4-[4-(benzyloxy)phenyl]-3-([(4-methylphenyl)methyl]sulfanyl)-4,5-dihydro-1H-1,2,4-triazol-5-one
-
4-[5-(4-[[2-(4-aminophenyl)-1H-benzimidazol-6-yl]oxy]phenoxy)-1H-benzimidazol-2-yl]aniline
4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
4-[8-(2,4-diphenyl-1H-imidazol-5-yl)dibenzo[b,d]furan-2-yl]-2,5-diphenyl-1H-imidazole)
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzoic acid
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
5,5'-dithiobis(2-nitrobenzoic acid)
5-bromo-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
-
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(2,4,5-trimethoxyphenyl)-1H-imidazole
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-1H-imidazole
6-(4-chlorobenzyl)-7-(2,2-dimethylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cyclooctylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-piperidin-1-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(3,3-dimethylbutyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(3-cyclohexylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(4,4-dimethylpentyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-[2-(3-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-[[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
6-[[4-(1-acetylpiperidin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
6-[[4-(4-acetyl-1,4-diazepan-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
6-[[4-(4-acetylpiperazin-1-yl)-3-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4,4-difluorocyclohexyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
7-(2-cyclohexylethyl)-6-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-(phenoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[(phenylamino)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[(pyridin-2-yloxy)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[(pyridin-2-ylsulfanyl)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[[methyl(phenyl)amino]methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
acetyl-Leu-Leu-Tyr-CHN2
-
-
acetyl-prolyl-leucyl-leucyl-leucinal
-
-
acetyl-prolyl-prolyl-leucyl-leucyl-leucinal
-
-
agathisflavone
noncompetitive inhibitor
alpha2 cysteine-proteinase inhibitor
-
-
-
Aprotinin
55.22% inhibition at 0.1 mM
Azodicarboxylic acid alpha-morpholide
-
-
benzamidine
17% inhibition at 5 mM
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-naphthylen-2-yl)amide
-
-
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-phenyl-ethyl)amide
-
-
benzophenone thiosemicarbazone
-
benzoylbenzophenone thiosemicarbazone
molecular docking in the active site
benzyl 1-cyano-3-pyrrolidinylcarbamate
-
IC50: 0.000054 mM
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxo-3-(1,1':4',1''-terphenyl-4-yl)propan-2-yl]carbamate
-
-
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(2'-methylbiphenyl-4-yl)-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(3'-methylbiphenyl-4-yl)-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(4'-methylbiphenyl-4-yl)-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-3-(3'-aminobiphenyl-4-yl)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-3-(3'-chlorobiphenyl-4-yl)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-3-(biphenyl-4-yl)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamate
-
-
benzyloxycarbonyl-FF-fluoromethylketone
-
cathepsin L-specific inhibitor
benzyloxycarbonyl-iodophenylalanine-Ala-CHN2
-
-
benzyloxycarbonyl-iodotyrosine-Ala-CHN2
-
-
benzyloxycarbonyl-L-Phe-L-Phe-fluoromethylketone
benzyloxycarbonyl-Leu-homophenylalanine-CHN2
-
-
benzyloxycarbonyl-Leu-Leu-Phe-CHN2
-
-
benzyloxycarbonyl-Leu-Leu-Tyr-CHN2
-
-
benzyloxycarbonyl-Leu-Met-CHN2
-
-
benzyloxycarbonyl-Leu-Trp-CHN2
-
-
benzyloxycarbonyl-Leu-Tyr-CHN2
-
-
benzyloxycarbonyl-leucyl-leucyl-leucinal
-
-
Benzyloxycarbonyl-Phe-Ala-CHN2
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
benzyloxycarbonyl-Phe-Arg-diazomethyl ketone
-
more than 99% inhibition at 0.1 mM
benzyloxycarbonyl-Phe-Phe fluoromethylketone
-
cell-permeable irreversible cathepsin inhibitor
Benzyloxycarbonyl-Phe-Phe-CHN2
benzyloxycarbonyl-Phe-Phe-fluoromethyl ketone
-
benzyloxycarbonyl-Phe-Phe-fluoromethylketone
-
-
benzyloxycarbonyl-Phe-Tyr-(tert-butyl)-diazomethylketone
benzyloxycarbonyl-Phe-Tyr-CHO
benzyloxycarbonyl-Phe-X-CHN2
-
-
benzyloxycarbonyl-PheTyr-[tert-butyl]-diazomethylketone
-
specific inhibitor
benzyloxycarbonyl-Tyr-Ala-CHN2
-
-
biphenyl-4-yl-acetylasparagine-D-Arg-Phe-Phe-NH2
-
biphenyl-4-yl-acetylcysteine-D-Arg-Abu-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-Arg-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-Phe-NH2
-
biphenyl-4-yl-acetylcysteine-D-Arg-Trp-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-Tyr-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Leu-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Met-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
the inhibitor shows a 310fold and 210fold selectivity for cathepsin L over cathepsin K and B, respectively
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(3-phenylpropyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(benzyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-Phe-NH2
-
biphenyl-4-yl-acetylmethylcysteine-D-Orn-Phe-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-Gly-Phe-Phe-NH2
-
biphenyl-4-yl-acetylnorvaline-D-Arg-Phe-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylserine-D-Arg-Phe-Phe-NH2
-
biphenylacetyl-(N6-biphenylacetyl)-Lys-D-Arg-Tyr-N-phenylethyl
-
biphenylacetyl-(N6-biphenylacetyl)Lys-D-Arg-Phe-N-phenylethyl
-
biphenylacetyl-MCys-D-Arg-Phe-N-phenylethyl
-
bis[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methanone
CA-074
i.e. N-(L-3-trans-propylcarbamoyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline, about 25% residual activity at 0.02 mM; i.e. N-(L-3-trans-propylcarbamoyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline, about 75% residual activity at 0.02 mM
Ca2+
-
51% residual activity at 1 mM
CAA0225
-
i.e. (2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide]3-[[2-(4-hydroxy-phenyl)-ethyl]-amide], a cathepsin L-specific inhibitor
cathepsin K propeptide
-
-
-
cathepsin L inhibitor 1
-
cathepsin L inhibitor I
-
0.05 mM
cathepsin L inhibitor III
-
0.01 mM
cathepsin L propeptide
-
-
-
cathepsin S propeptide
-
-
-
chagasin mutant delta T31-T32
-
-
-
chagasin mutant P30A
-
-
-
chagasin mutant T31A
-
-
-
chagasin mutant T31A/T32A
-
-
-
chagasin mutant T31S
-
-
-
chagasin mutant T31V
-
-
-
chagasin mutant T31Y
-
-
-
chagasin mutant T32A
-
-
-
chagasin mutant T32S
-
-
-
chagasin mutant T32V
-
-
-
chagasin mutant T32Y
-
-
-
chagasin mutant W93A
-
-
-
Chloroquine
-
chloroquine inhibits the infection with live Nipah virus and Hendra virus at a concentration of 1 microM in vitro. The mechanism for the antiviral action likely is the inhibition of cathepsin L, which is essential for the processing of the viral fusion glycoprotein and the maturation of newly budding virions
CID 16725315
-
2% inhibition at 0.025 mM
CID 23631927
-
38% inhibition at 0.025 mM, sub-nanomolar slow-binding, reversible inhibitor of human cathepsin L with cathepsin L/B selectivity of above 700fold that blocks SARS-CoV and Ebola pseudotype virus entry in human cells
CLIK-181
cathepsin L-specific inhibitor
CLIK195
-
complete inhibition at 0.01 mM
cystatin alpha
-
0.05 mg/ml
-
diazinedicarboxylic acid bisdimethylamide
-
-
diazomethanes
-
irreversible inhibition of hydrolysis of leucine enkephalin
-
diethyl-cyanamide
-
IC50 is above 0.1 mM
EGTA
40.55% inhibition at 0.1 mM
endopin 2C
-
endopin 2C inactivaties cathepsin L by binding to the enzyme, after dissociation from cathepsin L its activity is recovered within 60 min
-
Fe2+
-
5% residual activity at 1 mM
Fe3+
-
complete inhibition at 1 mM
fragment p41 of major histocompatibility complex class II-associated invariant chain
-
glucose
-
high concentrations
iodoacetate
-
complete inhibition at 1 mM
isonicotinyl-leucyl-leucyl-leucinal
-
-
JPM-565
-
cathepsin L irreversible binding
JPM-OEt
-
cathepsin L irreversible binding
KAPR-acetyl-K-QLATKAARKSAPA
-
KAPRKQLAT-acetyl-K-AARKSAPA
-
KAPRKQLATKAAR-dimethyl-K-SAPA
-
L-1-tosyl-2-phenylethylchloromethylketone
-
-
L-3-carboxy-trans-2,3-epoxypropionyl-leucylamido-(3-methyl)butane
-
-
L-3-trans-propylcarbamoyloxirane-2-carbonyl-L-isoleucyl-L-proline
-
-
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
the susceptibility of recombinant enzyme to substrate inhibition at 25°C is partially reversible, i.e., it is absent at 37°C and is displayed when the same enzyme sample is assayed again at 25°C
L-trans-epoxy-succinyl-leucylamido-(4-guanidino)-butane
-
complete inhibition at 0.1 mM
L-trans-epoxysuccinyl-leucylamido(3-methyl)butane
-
-
L-trans-epoxysuccinyl-leucylamido-(4-guanidino)butane
E-64
L-trans-epoxysuccinylleucylamido-(4-guanidino)butane
i.e. E-64, complete inhibition at 0.26 mM
LFLRL
-
0.05 mM, 78% inhibition
LFLTR-NH2
-
IC50: 0.0008 mM
LKFTF
-
0.05 mM, 24% inhibition; 0.05 mM, 32% inhibition
LKFTR
-
0.05 mM, 78% inhibition
LKLFF
-
0.05 mM, 42% inhibition
LKLFW
-
0.05 mM, 22% inhibition
LKLLW
-
0.05 mM, 75% inhibition
LLFLW
-
0.05 mM, 52% inhibition
LLFRW
-
0.05 mM, 52% inhibition
LLLLR
-
0.05 mM, 62% inhibition
LLLLW
-
0.05 mM, 37% inhibition
LLLRW
-
0.05 mM, 83% inhibition
LLLTB
-
0.05 mM, 58% inhibition
LLLTL
-
0.05 mM, 67% inhibition
LLLTR-NH2
-
IC50: 0.0005 mM
LLLTW
-
0.05 mM, 62% inhibition
LLYLW
-
0.05 mM, 47% inhibition
LLYTB
-
0.05 mM, 25% inhibition
LLYTR
-
0.05 mM, 62% inhibition
LLYTW
-
0.05 mM, 30% inhibition
low-MW cysteine proteinase inhibitor
-
-
-
LRFTF
-
0.05 mM, 25% inhibition
LRLLW
-
0.05 mM, 73% inhibition
LWFFW
-
0.05 mM, 61% inhibition
LWFRQ
-
0.05 mM, 20% inhibition
LWFRW
-
0.05 mM, 20% inhibition
LWLFL
-
0.05 mM, 73% inhibition
LWLFW
-
0.05 mM, 31% inhibition
LWLLW
-
0.05 mM, 52% inhibition
MENT
-
potent and very specific irreversible cathepsin L inhibitor
-
methyl (13alpha,17alpha,20S,24Z)-3-hydroxylanosta-7,24-dien-26-oate
-
competitive inhibition
methyl (3Z,13alpha,17alpha,20S,24Z)-3-(hydroxyimino)lanosta-7,24-dien-26-oate
-
competitive inhibition
methyl 5-acetyloxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
-
furanquinone from Paulownia tomentosa stem, inhibitory to both cathepsin L and cathepsin K
methyl 5-hydroxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
-
furanquinone from Paulownia tomentosa stem, inhibitory to both cathepsin L and cathepsin K
methylphenylazoformate
-
-
Mg2+
-
66% residual activity at 1 mM
morpholinurea-leucyl-homophenyl-vinyl sulfone phenyl
moderate inhibitor
morpholinylsuccinyl-leucyl-leucyl-leucinal
-
-
N-(1-cyano-3-pyrrolidinyl)benzamide
-
IC50: 0.00175 mM
N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide
-
IC50: 0.00008 mM
N-(1-cyano-3-pyrrolidinyl)[1,1'-biphenyl]-4-carboxamide
-
IC50: 0.00085 mM
N-(1-cyanopyrrolidin-3-yl)benzenesulfonamide
-
-
N-(2,6-dimethylbenzoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(2-chloro-5-nitrobenzoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(3-phenylpropanoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(4-benzyl-1-methylpiperidin-4-yl)-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-(4-biphenylacetyl)-S-methylcysteine-(D)-Arg-Phe-beta-phenethylamide
-
also called Cat L inhibitor 7, specific inhibitor
N-(4-bromobenzoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
N-(4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)propanamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
N-(biphenyl-4-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-(cyclopent-1-en-1-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-(naphthalen-2-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-(pentafluorobenzoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(piperidin-2-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-(pyridin-2-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-acetyl-Leu-Leumethional
inhibition of gelatinolytic activity
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)oxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-benzyl-2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-benzyl-2-[bis(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
N-benzyloxycarbonyl-Phe-Phe-fluoromethylketone
-
-
N-benzyloxycarbonyl-phenylalanyl-phenylalanine-fluoromethyl ketone
an irreversible cathepsin inhibitor
N-ethylmaleimide
10 mM, less than 10% residual activity
N-[(1-cyano-2-pyrrolidinyl)methyl]benzamide
-
IC50: 0.023 mM
N-[(1-cyano-2-pyrrolidinyl)methyl]benzenesulfonamide
-
IC50: 0.0115 mM
N-[(1-cyano-3-azetidinyl)methyl]benzamide
-
IC50: 0.00065 mM
N-[(1-cyano-3-azetidinyl)methyl]benzenesulfonamide
-
IC50: 0.00005 mM
N-[(1-cyano-3-azetidinyl)methyl]cyclohexanecarboxamide
-
IC50: 0.000006 mM
N-[(1-cyano-3-pyrrolidinyl)methyl]benzenesulfonamide
-
IC50: 0.00035 mM
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylpropyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-[(1S)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-[(2R)-2-[(2-amino-2-oxoethyl)amino]-2-[[(benzyloxy)carbonyl]amino]acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2R)-2-[(3-aminopropyl)amino]-2-[[(benzyloxy)carbonyl]amino]acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2R)-2-[[(benzyloxy)carbonyl]amino]-2-(3a,7a-dihydro-1H-indol-3-ylamino)acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2R)-2-[[(benzyloxy)carbonyl]amino]-2-(propan-2-ylamino)acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2R)-2-[[(benzyloxy)carbonyl]amino]-2-[(2-carbamimidamidoethyl)amino]acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2S)-1-(1H-indol-3-yl)-3-oxopropan-2-yl]-N2-(naphthalen-1-ylsulfonyl)-L-isoleucinamide
-
-
N-[(2S)-1-(3-chlorophenyl)-3-[(cyanomethyl)amino]but-3-en-2-yl]benzamide
-
-
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-1,3-dimethyl-1H-pyrazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-1-methyl-3-(propan-2-yl)-1H-pyrazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,3-dimethylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,4-dimethyl-1,3-thiazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,5-dimethyl-1,3-oxazole-4-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,5-dimethylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,5-dimethylthiophene-3-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2-methylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3,5-dimethylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3,7-dimethylnaphthalene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3-methylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-4-methylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-5,6,7,8-tetrahydronaphthalene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]benzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]cycloheptanecarboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]cyclohex-1-ene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]cyclohexanecarboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]naphthalene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]quinoline-4-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-4-methyl-1-oxo-1-[[(4S)-3-oxo-1-(pyridin-2-ylsulfonyl)azepan-4-yl]amino]pentan-2-yl]-1-benzofuran-2-carboxamide
-
-
N-[(4'-carboxy-2,2'-bipyridin-4-yl)carbonyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(6-aminopyridin-3-yl)carbonyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-3-(1H-indazol-1-yl)-L-alanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-3-(1H-indol-1-yl)-L-alanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-4-(thiophen-2-yl)-L-phenylalanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-L-leucyl-N-[(3S)-7-amino-1-[(2,6-dimethylbenzoyl)oxy]-2-oxoheptan-3-yl]-L-phenylalaninamide
-
irreversible inhibitor
N-[(benzyloxy)carbonyl]-L-phenylalanyl-3-(1H-imidazol-1-yl)-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-4-amino-L-phenylalaninamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-6-hydroxy-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-argininamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-leucinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-methioninamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-ornithinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-valinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-N6-methyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-L-tryptophyl-N-[(3S)-7-amino-1-[(2,6-dimethylbenzoyl)oxy]-2-oxoheptan-3-yl]-L-phenylalaninamide
-
irreversible inhibitor
N-[(benzyloxy)carbonyl]-L-tyrosyl-L-lysinamide
-
-
N-[3-(4-hydroxyphenyl)propanoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[3-(acetyloxy)benzoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,2-diphenylacetamide
N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide
N-[4-(acetyloxy)benzoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[4-(dimethylamino)benzoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[4-(trifluoromethyl)benzoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide
32% inhibition of FhCL3; 6% inhibition of FhCL1
N-[4-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]phenyl]acetamide
12% inhibition of FhCL3; 14% inhibition of FhCL1
N-[4-[(1Z)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide
13% inhibition of FhCL3
N-[6-[(6-[3,3-dimethyl-2-[(1E,3E,5E)-5-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)penta-1,3-dien-1-yl]-3H-indolium-1-yl]hexanoyl)amino]hexanoyl]-L-histidyl-L-threonyl-N-[(2R)-1-(benzylsulfanyl)-4-[(2,6-dimethylbenzoyl)oxy]-3-oxobutan-2-yl]-2,3,4,5,6-pentafluoro-L-phenylalaninamide
-
N2-acetyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-tryptophanamide
-
potent inhibitor
N2-[(benzyloxy)carbonyl]-L-arginyl-N-[(3S)-7-amino-1-[(2,6-dimethylbenzoyl)oxy]-2-oxoheptan-3-yl]-L-phenylalaninamide
-
irreversible inhibitor
N2-[(benzyloxy)carbonyl]-L-lysyl-N-[4-([[(5-methyl-7-oxo-7,8-dihydronaphthalen-2-yl)carbamoyl]oxy]methyl)phenyl]-L-lysinamide
-
N2-[(benzyloxy)carbonyl]-L-ornithyl-N-[(3S)-7-amino-1-[(2,6-dimethylbenzoyl)oxy]-2-oxoheptan-3-yl]-L-phenylalaninamide
-
irreversible inhibitor
N2-[(benzyloxy)carbonyl]-N-[(3S)-1-cyanopyrrolidin-3-yl]-L-leucinamide
-
-
Nalpha-[(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)carbonyl]-3-chloro-N-(cyanomethyl)-L-phenylalaninamide
-
pH and temperature not specified in the publication
Nalpha-[(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)carbonyl]-N-(cyanomethyl)-3-methyl-L-phenylalaninamide
-
pH and temperature not specified in the publication
Nalpha-[(benzyloxy)carbonyl]-N-[(1R)-1,2-diamino-2-oxoethyl]-L-phenylalaninamide
-
-
Nalpha-[(benzyloxy)carbonyl]-N-[(3S)-7-[(6-[(2Z)-3,3-dimethyl-5-sulfo-2-[(2E,4E)-5-(1,3,3-trimethyl-5-sulfo-2,3-dihydro-1H-indol-2-yl)penta-2,4-dien-1-ylidene]-2,3-dihydro-1H-indol-1-yl]hexanoyl)amino]-2-oxo-1-(2,3,5,6-tetrafluoro-4-[[2-([[1-(2-[(3E)-3-(5-sulfo-2,3-dihydro-1H-indolium-1-ylidene)-6-(5-sulfo-2,3-dihydro-1H-indol-1-yl)-3H-xanthen-9-yl]benzene-1-sulfonyl)piperidin-4-yl]carbonyl]amino)ethyl]carbamoyl]phenoxy)heptan-3-yl]-L-phenylalaninamide
-
naphthalene-2-carboxylic acid ((S)-2-naphthalen-2-yl-1-[(S)-3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]ethyl)amide
-
-
naphthoic-1-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
Ni2+
-
complete inhibition at 1 mM
nicotinyl-leucyl-leucyl-leucinal
-
-
OC-1DELTAD86
-
0.002 mM
-
ortho-aminobenzoic acid-LFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
ortho-aminobenzoic acid-VLFEKKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
ortho-aminobenzoic acid-VLFEKKVYLQ-N-[2,4-dinitrophenyl]ethylenediamine
-
efficient cathepsin L inhibitor
ortho-aminobenzoic acid-VLFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
p-hydroxymercuribenzoate
-
-
p41-fragment-mouse
64 residues present in the p41 form of the murine major histocompatibility complex II (MHCII)-associated invariant chain
-
P41icf
-
synthesis and NMR structure of the potent inhibitor
-
pepstatin A
21.54% inhibition at 0.1 mM
Phe-Tyr-(OBut)-COCHO
potent, reversible, synthetic peptidyl inhibitor of cathepsin L
Phe-Tyr-(tert-Bu)-diazomethylketone
irreversible inhibitor that can inactivate cathepsin L at micromolar concentrations
Phenylbutazone
-
noncompetitive inhibitor
phenylmethanesulfonyl fluoride
-
-
phenylmethylsulfonyl fluoride
Protein C inhibitor
-
inhibits cathepsin L with an inhibition rate (k2) of 30000 0 M-1 s-1
-
quinoline-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
quinoline-8-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
RFLRW
-
0.05 mM, 21% inhibition
RFLYR
-
0.05 mM, 64% inhibition
RKLFL
-
0.05 mM, 79% inhibition
RKLLW-NH2
-
IC50: 0.0006 mM
RKLWD-NH2
-
IC50: 0.014 mM
RKLWF
-
0.05 mM, 52% inhibition
RKLWL-NH2
-
IC50: 0.0008 mM
RKLWV
-
0.05 mM, 41% inhibition
RLLLW
-
0.05 mM, 75% inhibition
RLLYW
-
0.05 mM, 29% inhibition
RRFYV
-
0.05 mM, 24% inhibition
RRLTW
-
0.05 mM, 38% inhibition
RRYLB
-
0.05 mM, 33% inhibition
RWLTL
-
0.05 mM, 61% inhibition
RWLYL
-
0.05 mM, 65% inhibition
S-(2-oxo-1-phenylpyrrolidin-3-yl) 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
S-[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoyl]hydrazinecarbothioate
-
-
salicylic acid
-
and its m-analogs and p-analogs
SDS
6.53% residual activity at 0.05% (w/v)
serpin B3
-
about 35% inhibition at 7.5 nM, the presence of heparin accelerates inhibition of cathepsin L by serpin B3 (4.1fold increase in rate of inhibition)
-
serpin B4
-
about 70% inhibition at 100 nM, the presence of 50 nM heparin accelerates inhibition of cathepsin L by serpin B4 (4.1fold increase in rate of inhibition)
-
soluble type I collagen
inhibitory against cathepsin L, Ki is 0.36 mg/ml, collagen is also a substrate for the enzyme
-
Soybean trypsin inhibitor
-
63.12% residual activity at 0.05 mg/ml
-
Stefin B
a potent cathepsin L inhibitor, colorectal carcinoma cells reveal only very faint amounts of immunolabeled stefin B within their nuclei, while it is prominently present within the cytoplasm of Caco-2 and SW-620 cells, and mostly associated with the cytoplasmic face of vesicles in HCT-116 cells
-
tert-butyloxycarbonyl-Lys(epsilon-9-fluorenylmethoxycarbonyl)-Leu-Tyr-CHN2
-
-
tert-butyloxycarbonyl-Lys-Leu-Tyr-CHN2
-
-
tert-butyloxycarbonyl-Val-Lys(epsilon-benzyloxycarbonyl)-Leu-Tyr-CHN2
-
-
testican-1
-
strong competitive inhibitor, inhibition is independent of its chondroitin sulfate chains and is effective at both pH 5.5 and pH 7.2, does not inhibit the structurally related lysosomal cysteine protease cathepsin B
-
tetrahydrorobustaflavone
uncompetitive inhibitor
Tg1 domain of testican-1
-
-
-
thyroglobulin type-1 domain
-
-
-
TLCK
10 mM, less than 10% residual activity
tosyl phenylalanyl chloromethylketone
-
66.63% residual activity at 0.1 mg/ml
toxostatin
-
endogenous inhibitor, acts both on cathepsin L and cathepsin B in the nanomolar range
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
YFLLR
-
0.05 mM, 30% inhibition
YFLTF
-
0.05 mM, 29% inhibition
YKLLR
-
0.05 mM, 72% inhibition
YLLFW
-
0.05 mM, 37% inhibition
YLYLF
-
0.05 mM, 40% inhibition
YWFTF
-
0.05 mM, 43% inhibition
YWLLR
-
0.05 mM, 73% inhibition
YWYYL
-
0.05 mM, 20% inhibition
YYLLR
-
0.05 mM, 56% inhibition
Z-Phe-Phe-CH2F
-
i.e. inhibitor I, blocks sea urchin embryogenesis. Complete arrest of cell division is obtained when the embryos are incubated with 100 microM of inhibitor I
Z-Phe-Tyr-CHO
-
specifically inhibits cathepsin L
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
-
i.e. CAA0225. Significantly inhibits degradation of long-lived proteins in HeLa and Huh-7 cells cultured under nutrient-deprived conditions. CAA0225 effectively inhibits degradation of microtubule-associated protein IA/IB light chain 3-II and gamma-aminobutyric acid (A) receptor-associated protein
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
-
i.e. CAA0225. IC50 value for rat liver cathepsin B above 1 microM
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
-
specific inhibitor, CAA0225, more than 99% inhibition at 0.1 mM
(N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide)
-
(N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide)
-
(N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide)
-
1,10-phenanthroline
-
-
1,10-phenanthroline
36.6% inhibition at 0.1 mM
1-naphthalenesulfonyl-Ile-Trp-aldehyde
-
cathepsin L inhibitor
1-naphthalenesulfonyl-Ile-Trp-aldehyde
-
selective intra- and extracellular cathepsin L inhibitor
2,6-dimethoxy-4-[4-(4-phenoxyphenyl)-5-phenyl-1H-imidazol-2-yl]phenol
-
2,6-dimethoxy-4-[4-(4-phenoxyphenyl)-5-phenyl-1H-imidazol-2-yl]phenol
-
2,6-dimethoxy-4-[4-(4-phenoxyphenyl)-5-phenyl-1H-imidazol-2-yl]phenol
the compound shows significant inhibitory activity against rhodesain, but displays poor antitrypanosomal activity at 0.020 mM
2,6-dimethoxy-4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
-
2,6-dimethoxy-4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
-
2,6-dimethoxy-4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
-
2-(1,3-benzodioxol-5-yl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
2-(1,3-benzodioxol-5-yl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
2-(1,3-benzodioxol-5-yl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
2-(3,4-dimethoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
2-(3,4-dimethoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
2-(3,4-dimethoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
2-(4-methoxyphenyl)-4-[8-[2-(4-methoxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
-
2-(4-methoxyphenyl)-4-[8-[2-(4-methoxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
-
2-(4-methoxyphenyl)-4-[8-[2-(4-methoxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
-
2-(4-methoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
2-(4-methoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
2-(4-methoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
2-(acetylamino)-N-[4-(6-[[2-(acetylamino)benzoyl]amino]-1H-benzimidazol-2-yl)phenyl]benzamide
-
2-(acetylamino)-N-[4-(6-[[2-(acetylamino)benzoyl]amino]-1H-benzimidazol-2-yl)phenyl]benzamide
-
2-(acetylamino)-N-[4-(6-[[2-(acetylamino)benzoyl]amino]-1H-benzimidazol-2-yl)phenyl]benzamide
-
2-(furan-2-yl)-4-[8-[2-(furan-2-yl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
-
2-(furan-2-yl)-4-[8-[2-(furan-2-yl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
-
2-(furan-2-yl)-4-[8-[2-(furan-2-yl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
-
4,4'-[methanediylbis(1H-benzimidazole-5,2-diyl)]dianiline
-
4,4'-[methanediylbis(1H-benzimidazole-5,2-diyl)]dianiline
-
4,4'-[methanediylbis(1H-benzimidazole-5,2-diyl)]dianiline
has H-bond and steric interactions with Cys 25 of rhodesain's catalytic triad as well as residues Leu67 and Met68 while its dianiline motifs have steric interactions with Gly64 and Leu160
4-(4-[8-[2-(4-carboxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)benzoic acid
-
4-(4-[8-[2-(4-carboxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)benzoic acid
-
4-(4-[8-[2-(4-carboxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)benzoic acid
-
4-(4-[8-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)phenol
-
4-(4-[8-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)phenol
-
4-(4-[8-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)phenol
-
4-amino-N-(4-[6-[(4-aminobenzoyl)amino]-1H-benzimidazol-2-yl]phenyl)benzamide
-
4-amino-N-(4-[6-[(4-aminobenzoyl)amino]-1H-benzimidazol-2-yl]phenyl)benzamide
-
4-amino-N-(4-[6-[(4-aminobenzoyl)amino]-1H-benzimidazol-2-yl]phenyl)benzamide
the compound shows significant inhibitory activity against rhodesain, but displays poor antitrypanosomal activity at 0.020 mM
4-[(E)-benzylideneamino]-N-[4-[6-([4-[(E)-benzylideneamino]benzoyl]amino)-1H-benzimidazol-2-yl]phenyl]benzamide
-
4-[(E)-benzylideneamino]-N-[4-[6-([4-[(E)-benzylideneamino]benzoyl]amino)-1H-benzimidazol-2-yl]phenyl]benzamide
-
4-[(E)-benzylideneamino]-N-[4-[6-([4-[(E)-benzylideneamino]benzoyl]amino)-1H-benzimidazol-2-yl]phenyl]benzamide
the compound shows significant inhibitory activity against rhodesain, but displays poor antitrypanosomal activity at 0.020 mM
4-[4-(5,5-dioxidodibenzo[b,d]thiophen-2-yl)-5-phenyl-1H-imidazol-2-yl]-2,6-dimethoxyphenol
-
4-[4-(5,5-dioxidodibenzo[b,d]thiophen-2-yl)-5-phenyl-1H-imidazol-2-yl]-2,6-dimethoxyphenol
-
4-[4-(5,5-dioxidodibenzo[b,d]thiophen-2-yl)-5-phenyl-1H-imidazol-2-yl]-2,6-dimethoxyphenol
-
4-[5-(4-[[2-(4-aminophenyl)-1H-benzimidazol-6-yl]oxy]phenoxy)-1H-benzimidazol-2-yl]aniline
-
4-[5-(4-[[2-(4-aminophenyl)-1H-benzimidazol-6-yl]oxy]phenoxy)-1H-benzimidazol-2-yl]aniline
-
4-[5-(4-[[2-(4-aminophenyl)-1H-benzimidazol-6-yl]oxy]phenoxy)-1H-benzimidazol-2-yl]aniline
-
4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
-
4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
-
4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
-
4-[8-(2,4-diphenyl-1H-imidazol-5-yl)dibenzo[b,d]furan-2-yl]-2,5-diphenyl-1H-imidazole)
-
4-[8-(2,4-diphenyl-1H-imidazol-5-yl)dibenzo[b,d]furan-2-yl]-2,5-diphenyl-1H-imidazole)
-
4-[8-(2,4-diphenyl-1H-imidazol-5-yl)dibenzo[b,d]furan-2-yl]-2,5-diphenyl-1H-imidazole)
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
-
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(2,4,5-trimethoxyphenyl)-1H-imidazole
-
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(2,4,5-trimethoxyphenyl)-1H-imidazole
-
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(2,4,5-trimethoxyphenyl)-1H-imidazole
the compound shows significant inhibitory activity against rhodesain, but displays poor antitrypanosomal activity at 0.020 mM
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-1H-imidazole
-
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-1H-imidazole
-
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-1H-imidazole
-
6-[[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4,4-difluorocyclohexyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4,4-difluorocyclohexyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
antipain
-
1 mM, complete loss of activity
antipain
97.26% inhibition at 0.1 mM
benzyloxycarbonyl-L-Phe-L-Phe-fluoromethylketone
-
-
benzyloxycarbonyl-L-Phe-L-Phe-fluoromethylketone
-
irreversible and selective inhibitor of cathepsin L
benzyloxycarbonyl-L-Phe-L-Phe-fluoromethylketone
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
benzyloxycarbonyl-Phe-Tyr-(tert-butyl)-diazomethylketone
-
irreversible cathepsin L inhibitor
benzyloxycarbonyl-Phe-Tyr-(tert-butyl)-diazomethylketone
-
-
benzyloxycarbonyl-Phe-Tyr-CHO
-
-
benzyloxycarbonyl-Phe-Tyr-CHO
-
-
benzyloxycarbonyl-Phe-Tyr-CHO
-
-
benzyloxycarbonyl-Phe-Tyr-CHO
-
-
bis[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methanone
-
bis[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methanone
-
bis[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methanone
the compound shows significant inhibitory activity against rhodesain, but displays poor antitrypanosomal activity at 0.020 mM
CA-074Me
-
in cells transfected with Nipah virus fusion protein, treatment with inhibitor CA-074ME almost completely prevents proteolytic processing of F0 into F1 and F2
CA-074Me
-
cathepsin L activity is suppressed by 0.04 mM CA-074Me in NIH-3T3 cells
chymostatin
-
-
chymostatin
-
93% inhibition at 5 mM
chymostatin
-
32.24% residual activity at 0.2 mM
chymostatin
95% inhibition at 0.1 mM
chymostatin
21.29% inhibition at 0.1 mM
CLIK-148
-
CLIK-148
cathepsin L-specific inhibitor
CLIK-148
treatment of AtT-20 cells results in reduced production of adrenocorticotropic hormone and accumulation of proopiomelanocortin
CLIK-148
-
specific cathepsin L inhibitor
CLIK-148
-
specific inhibitor of cathepsin L
CLIK148
0.1 mM
CLIK148
cathepsin L-specific inhibitor
CLIK148
-
complete inhibition at 0.01 mM
CLIK148
-
cathepsin L-specific inhibitor
CLIK148
-
cathepsin L-specific inhibitor, CLIK148 attenuates Eco-MLV infection in NIH3T3 cells
CLIK148
-
cathepsin L-specific inhibitor
Co2+
-
complete inhibition at 1 mM
Co2+
8.01% residual activity at 5 mM
Co2+
58.88% residual activity at 5 mM
Cu2+
-
1 mM, 19% residual activity
Cu2+
-
complete inhibition at 1 mM
Cu2+
complete inhibition at 5 mM
CuCl2
-
-
Cys
-
-
cystatin
-
from chicken, activity with benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
cystatin
-
important role of Gly4 in the binding to the enzyme
-
cystatin A
-
-
-
cystatin B
-
-
-
cystatin B
-
cystatin B (stefin B) plays an important role in regulating the proteolytic activity of cathepsin L in the nucleus by protecting the CUX1 transcription factor and probably other substrates from proteolytic cleavage by cathepsin L
-
cystatin C
-
-
-
cystatin D
-
-
-
cystatin F
-
-
-
E-64
complete inhibition
E-64
-
almost complete inhibition at 0.01 mM
E-64
-
i.e. L-trans-epoxysuccinyl-leucylamide-(4-guanido)-butane, 24.76% residual activity at 1 mg/ml
E-64
98% inhibition at 0.01 mM
E-64
-
activity with benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
E-64
-
irreversible inhibitor
E-64
-
broad-spectrum cathepsin inhibitor, cathepsin L irreversible binding
E-64
-
i.e. 1-[N-[(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl]amino]-4-guanidinobutane
E-64
a broad-spectrum cysteine peptidase inhibitor
E-64
a pan cysteine cathepsin inhibitor
E-64
-
complete inhibition at 0.1 mM
E-64
i.e. transepoxysuccinyl-L-leucyl-amido(4-guanidino) butane, 60.1% inhibition at 0.5 mM
E-64
-
i.e. L-trans-epoxy-succinyl-leucylamido-(4-guanidino)-butane
E-64
i.e. trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane; i.e. trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
E-64
99.7% inhibition at 0.01 mM
E-64d
-
in cells transfected with Nipah virus fusion protein, treatment with inhibitor E-64d almost completely prevents proteolytic processing of F0 into F1 and F2
E64
0.1 mM, complete inhibition
E64
inhibition of gelatinolytic activity
EDTA
5 mM, 81% residual activity
EDTA
-
98% residual activity at 2 mM
EDTA
10.81% inhibition at 0.1 mM
endopin 2
-
endogenous protease inhibitor. High level of co-localization with enkephalin and NPY neuropeptides present in secretory vesicles of adrenal medullary chriomaffin cells in primary culture. Expression in brain, pituitary, adrenal medulla, and other neuroendocrine tissues
-
endopin 2
-
enodgenous inhibitor, present in pituitary gland
-
Ep-460
-
-
Ep-475
-
-
Ep-475
-
cathepsin L irreversible binding
fragment p41 of major histocompatibility complex class II-associated invariant chain
inhibitory to human cathepsin V, cathepsin L, cathepsin K, cathepsin F with Ki values in the low nanomolar range. Ki values are sufficiently low to ensure complex formation at physiological concentrations. Regulation of the proteolytic activity of most of the cysteine cathepsins by the p41 fragment is an important and widespread control mechanism of antigen presentation
-
fragment p41 of major histocompatibility complex class II-associated invariant chain
inhibitory to human cathepsin V, cathepsin L, cathepsin K, cathepsin F with Ki values in the low nanomolar range. Ki values are sufficiently low to ensure complex formation at physiological concentrations. Regulation of the proteolytic activity of most of the cysteine cathepsins by the p41 fragment is an important and widespread control mechanism of antigen presentation
-
Hg2+
-
-
Hg2+
37.32% residual activity at 1 mM
Hg2+
19.61% residual activity at 5 mM
iodoacetamide
complete inhibition
iodoacetic acid
-
1 mM, complete loss of activity
iodoacetic acid
10 mM, 15% residual activity
leupeptin
-
1 mM, 31% residual activity
leupeptin
0.1 mM, less than 10% residual activity
leupeptin
strong inhibition
leupeptin
-
about 95% inhibition at 0.1 mM
leupeptin
-
11.06% residual activity at 0.001 mg/ml
leupeptin
-
complete inhibition at 0.1 mM
leupeptin
98% inhibition at 0.1 mM
leupeptin
inhibition of gelatinolytic activity and of autolcleavage of cathepsin L
leupeptin
95.85% inhibition at 0.1 mM
leupeptin
-
reversible inhibition of hydrolysis of leucine enkephalin
leupeptin
-
pseudo-irreversible inhibitor
MDL28170
-
-
Mn2+
-
65% residual activity at 1 mM
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,2-diphenylacetamide
-
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,2-diphenylacetamide
-
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,2-diphenylacetamide
the compound shows significant inhibitory activity against rhodesain, but displays poor antitrypanosomal activity at 0.020 mM
N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide
-
N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide
-
N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide
-
NEM
40.84% inhibition at 0.1 mM
p-21s
-
c-Ha-ras gene product
-
p-21s
-
c-Ha-ras proteins produced by Escherichia coli potent inhibitor
-
p41-fragment-human
64 residues present in the p41 form of the human major histocompatibility complex II (MHCII)-associated invariant chain
-
p41-fragment-human
64 residues present in the p41 form of the human major histocompatibility complex II (MHCII)-associated invariant chain
-
PCMB
-
-
pefabloc
-
about 30% inhibition at 1 mM
pefabloc
-
78.43% residual activity at 2 mg/ml
pepstatin
0.01 mM, 90% residual activity
pepstatin
-
58.06% residual activity at 0.001 mg/ml
phenylmethylsulfonyl fluoride
10 mM, less than 10% residual activity
phenylmethylsulfonyl fluoride
10.6% inhibition at 0.1 mM
PMSF
low inhibition
PMSF
37.5% inhibition at 5 mM
quercetin
15% inhibition of FhCL1; 8% inhibition of FhCL3
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
slow binding and slowly reversible inhibitor. 7- to 151fold greater selectivity towards cathepsin L then papain and cathepsins B, K, V, and S with no activity against cathepsin G. Inhibitor lacks toxicitiy in human aortic endothelial cells and inhibits in vitro propagation of Plasmodium falciparum with an IC50 value of 15.4 microM and of Leishmania major with an IC50 value of 12.5 microM
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
CID16725315, slowly reversible inhibition
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
tosyl-Lys-CH2Cl
-
-
tosyl-Phe-CH2Cl
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
95% inhibition at 0.01 mM
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
i.e. E-64, irreversible
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
i.e. E-64, in vivo, the inhibitor is transported to the liver cytosol in the free form in the blood and permeated into the lysosomes, where it binds to, and inactivates the enzyme
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
Zn2+
-
1 mM, complete loss of activity
Zn2+
-
10% residual activity at 1 mM
Zn2+
14.75% residual activity at 5 mM
additional information
-
the enzyme is inhibited by cysteine proteases inhibitors
-
additional information
no inhibition by EDTA
-
additional information
-
no inhibition by EDTA
-
additional information
no inhibition by EDTA, AEBSF, approtinin, and pepstatin A
-
additional information
-
no inhibition by EDTA, AEBSF, approtinin, and pepstatin A
-
additional information
-
not inhibited by aprotinin and benzamidine
-
additional information
identification of chalcones as Fasciola hepatica cathepsin L inhibitors using a comprehensive experimental and computational approach, library screening, overview. No inhibition of cathepsin L1 by (2E)-1-(2-hydroxyphenyl)-3-[4-(methylsulfanyl)phenyl]prop-2-en-1-one, N-[4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide, and 2-(4-chlorophenyl)-4H-chromen-4-one; identification of chalcones as Fasciola hepatica cathepsin L inhibitors using a comprehensive experimental and computational approach, library screening, overview. No inhibition of cathepsin L3 by (2E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one, (2E)-1-(2-hydroxyphenyl)-3-(pyridin-2-yl)prop-2-en-1-one, and (2Z)-1-(2-hydroxyphenyl)-3-(pyridin-2-yl)prop-2-en-1-one; not inhibitory: (2E)-1-(2-hydroxyphenyl)-3-[4-(methylsulfanyl)phenyl]prop-2-en-1-one; not inhibitory: N-[4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide
-
additional information
identification of chalcones as Fasciola hepatica cathepsin L inhibitors using a comprehensive experimental and computational approach, library screening, overview. No inhibition of cathepsin L1 by (2E)-1-(2-hydroxyphenyl)-3-[4-(methylsulfanyl)phenyl]prop-2-en-1-one, N-[4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide, and 2-(4-chlorophenyl)-4H-chromen-4-one; identification of chalcones as Fasciola hepatica cathepsin L inhibitors using a comprehensive experimental and computational approach, library screening, overview. No inhibition of cathepsin L3 by (2E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one, (2E)-1-(2-hydroxyphenyl)-3-(pyridin-2-yl)prop-2-en-1-one, and (2Z)-1-(2-hydroxyphenyl)-3-(pyridin-2-yl)prop-2-en-1-one; not inhibitory: (2E)-1-(2-hydroxyphenyl)-3-[4-(methylsulfanyl)phenyl]prop-2-en-1-one; not inhibitory: N-[4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide
-
additional information
-
identification of chalcones as Fasciola hepatica cathepsin L inhibitors using a comprehensive experimental and computational approach, library screening, overview. No inhibition of cathepsin L1 by (2E)-1-(2-hydroxyphenyl)-3-[4-(methylsulfanyl)phenyl]prop-2-en-1-one, N-[4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide, and 2-(4-chlorophenyl)-4H-chromen-4-one; identification of chalcones as Fasciola hepatica cathepsin L inhibitors using a comprehensive experimental and computational approach, library screening, overview. No inhibition of cathepsin L3 by (2E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one, (2E)-1-(2-hydroxyphenyl)-3-(pyridin-2-yl)prop-2-en-1-one, and (2Z)-1-(2-hydroxyphenyl)-3-(pyridin-2-yl)prop-2-en-1-one; not inhibitory: (2E)-1-(2-hydroxyphenyl)-3-[4-(methylsulfanyl)phenyl]prop-2-en-1-one; not inhibitory: N-[4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide
-
additional information
structure-based design of enzyme inhibitors through a computational study that combined virtual screening, molecular dynamics simulations, and binding free energy calculations. Docking protocol validation is carried out through the non-covalent re-docking of nitrile ((2S,4R)-1-[1-(4-chlorophenyl) cyclopropyl] carbonyl-4-(2-chlorophenyl) sulfonyl-N-[1-(iminomethyl)cyclopropyl] pyrrolidine-2-carboxamide) inhibitor into the active site of this protease, three-dimensional structure determination using the crystal structure of proFhCL1 C25G (PDB ID 2O6X) as a template
-
additional information
-
structure-based design of enzyme inhibitors through a computational study that combined virtual screening, molecular dynamics simulations, and binding free energy calculations. Docking protocol validation is carried out through the non-covalent re-docking of nitrile ((2S,4R)-1-[1-(4-chlorophenyl) cyclopropyl] carbonyl-4-(2-chlorophenyl) sulfonyl-N-[1-(iminomethyl)cyclopropyl] pyrrolidine-2-carboxamide) inhibitor into the active site of this protease, three-dimensional structure determination using the crystal structure of proFhCL1 C25G (PDB ID 2O6X) as a template
-
additional information
-
not inhibited by CA074Me
-
additional information
-
not inhibited by EDTA
-
additional information
-
MHC class II-associated invariant chain fragment from human kidney that has inhibitory effect on the enzyme
-
additional information
-
no inhibition with 0.14 mM (2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylate, (2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate, (2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate, (2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate, or (2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
additional information
-
not inhibited by N-(L-3-trans-(propylcarbamoyl)oxilane-2-carbonyl)-L-isoluecyl-L-proline (CA-074)
-
additional information
-
heparin cofactor II and plasminogen activator inhibitor 1 do not inhibit cathepsin L
-
additional information
-
native cathepsin L was completely inhibited by 0.001, 0.004, or 0.01 mM cathepsin L propeptide (10 min, pH 6.5, room temperature)
-
additional information
-
histones do not inhibit cathepsin L activity even at a 100fold molar excess (0.00215 mM histone concentration)
-
additional information
endogenous cysteine peptidase inhibitors like stefin B act in safe-guarding mammalian cells by their presence in the cyto- or nucleoplasm, and thus protect from activities of proteolytic enzymes leaking into the cytoplasm upon, for instance, non-intended rupture of endolysosomes in pathological situations
-
additional information
development and synthesis of a clickable and tagless activity-based probes of cathepsin L, method, overview. The probe KDP-1 is highly efficient, active-site directed and activity-dependent, selective, cell penetrable, and non-toxic to human cells. Using a zebrafish model, it is schown that the probe can inhibit cathepsin L function in vivo during the hatching process. KDP-1 exhibits a strong time dependent inactivation of cathepsin L activity, although with about 10fold lower rate than KD-1
-
additional information
-
development and synthesis of a clickable and tagless activity-based probes of cathepsin L, method, overview. The probe KDP-1 is highly efficient, active-site directed and activity-dependent, selective, cell penetrable, and non-toxic to human cells. Using a zebrafish model, it is schown that the probe can inhibit cathepsin L function in vivo during the hatching process. KDP-1 exhibits a strong time dependent inactivation of cathepsin L activity, although with about 10fold lower rate than KD-1
-
additional information
synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L, molecular modeling, overview
-
additional information
-
synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L, molecular modeling, overview
-
additional information
screening and identification of inhibitors of Trypanosoma brucei cathepsin L with antitrypanosomal activity, overview
-
additional information
-
screening and identification of inhibitors of Trypanosoma brucei cathepsin L with antitrypanosomal activity, overview
-
additional information
no inhibition by EDTA, PMSF, and pepstatin A
-
additional information
-
no inhibition by EDTA, PMSF, and pepstatin A
-
additional information
-
insensitive to K+, phenylmethylsulfonylfluoride and pepstatin A
-
additional information
natural products as inhibitors of recombinant cathepsin L of Leishmania mexicana, overview
-
additional information
-
natural products as inhibitors of recombinant cathepsin L of Leishmania mexicana, overview
-
additional information
-
not inhibited by CA074Me
-
additional information
-
no inhibition by pepstatin, phenylmethane sulfonyl fluoride
-
additional information
not inhibited by N-ethylmaleimide, phenylmethylsulfonyl fluoride, antiprotinin, EDTA, EGTA, 1,10-phenanthroline, and pepstatin A
-
additional information
-
not inhibited by CA074Me
-
additional information
-
in vivo inhibitor from bovine skeletal muscle, purification, MW 30000 Da
-
additional information
screening and identification of inhibitors of Trypanosoma brucei cathepsin L with antitrypanosomal activity, overview
-
additional information
screening and identification of inhibitors of Trypanosoma brucei cathepsin L with antitrypanosomal activity, overview. No inhibition by 7 and 13
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
5.3
2-aminobenzoyl-Ala-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.8
2-aminobenzoyl-Arg-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.5
2-aminobenzoyl-Asn-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.8
2-aminobenzoyl-Gln-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.4
2-aminobenzoyl-Glu-Glu-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
4
2-aminobenzoyl-Glu-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.2
2-aminobenzoyl-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.1
2-aminobenzoyl-Gly-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
5.9
2-aminobenzoyl-His-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
2.3
2-aminobenzoyl-Ile-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.2
2-aminobenzoyl-Lys-Arg-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.4
2-aminobenzoyl-Lys-Asn-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.4
2-aminobenzoyl-Lys-Asp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.7
2-aminobenzoyl-Lys-Gln-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.4
2-aminobenzoyl-Lys-Glu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.5
2-aminobenzoyl-Lys-Gly-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.3
2-aminobenzoyl-Lys-His-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
2.3
2-aminobenzoyl-Lys-Ile-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.1
2-aminobenzoyl-Lys-Leu-Ala-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.7
2-aminobenzoyl-Lys-Leu-Arg-Arg-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
6.3
2-aminobenzoyl-Lys-Leu-Arg-Asn-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
5.8
2-aminobenzoyl-Lys-Leu-Arg-Gln-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
4.9
2-aminobenzoyl-Lys-Leu-Arg-Glu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.4
2-aminobenzoyl-Lys-Leu-Arg-Gly-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
7.3
2-aminobenzoyl-Lys-Leu-Arg-His-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.9
2-aminobenzoyl-Lys-Leu-Arg-Ile-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
4.1
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ala-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.6
2-aminobenzoyl-Lys-Leu-Arg-Ser-Arg-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
2.3
2-aminobenzoyl-Lys-Leu-Arg-Ser-Asn-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
4.2
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gln-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
4.1
2-aminobenzoyl-Lys-Leu-Arg-Ser-Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
4.8
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gly-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.7
2-aminobenzoyl-Lys-Leu-Arg-Ser-His-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
2.4
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ile-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
6
2-aminobenzoyl-Lys-Leu-Arg-Ser-Pro-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
4.6
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.2
2-aminobenzoyl-Lys-Leu-Arg-Ser-Val-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
5.5
2-aminobenzoyl-Lys-Leu-Arg-Val-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.1
2-aminobenzoyl-Lys-Leu-Asn-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.2
2-aminobenzoyl-Lys-Leu-Asp-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.9
2-aminobenzoyl-Lys-Leu-Gln-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
2.6
2-aminobenzoyl-Lys-Leu-Glu-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.4
2-aminobenzoyl-Lys-Leu-Gly-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.3
2-aminobenzoyl-Lys-Leu-His-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.4
2-aminobenzoyl-Lys-Leu-Ile-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
3.1
2-aminobenzoyl-Lys-Leu-Lys-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.4
2-aminobenzoyl-Lys-Leu-Met-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.1
2-aminobenzoyl-Lys-Leu-Pro-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.5
2-aminobenzoyl-Lys-Leu-Ser-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.3
2-aminobenzoyl-Lys-Leu-Thr-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.5
2-aminobenzoyl-Lys-Leu-Val-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.9
2-aminobenzoyl-Lys-Lys-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
4
2-aminobenzoyl-Lys-Met-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
13.5
2-aminobenzoyl-Lys-Phe-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.2
2-aminobenzoyl-Lys-Pro-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.9
2-aminobenzoyl-Lys-Ser-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
0.4
2-aminobenzoyl-Lys-Thr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
1.9
2-aminobenzoyl-Lys-Trp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
7.8
2-aminobenzoyl-Lys-Tyr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
6.4
2-aminobenzoyl-Lys-Val-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
2.1
2-aminobenzoyl-Val-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37°C
17.4
Abz-3-biphenyl-L-Ala-Arg-Ala-Ala-Tyr(3-NO2)-NH2
-
in 50 mM Mes buffer (pH 6.0) containing 5 mM dithiothreitol, at 37°C
27
Abz-3-biphenyl-L-Ala-Arg-Ala-Gln-Tyr(3-NO2)-NH2
-
in 50 mM Mes buffer (pH 6.0) containing 5 mM dithiothreitol, at 37°C
5.01
Abz-3-biphenyl-L-Ala-Arg-Ala-Ser-Tyr(3-NO2)-NH2
-
in 50 mM Mes buffer (pH 6.0) containing 5 mM dithiothreitol, at 37°C
0.49
Abz-PR-acetyl-K-QLATKAARKSAK-Dnp
pH and temperature not specified in the publication
0.37
Abz-PRKQLAT-acetyl-K-AARKSAK-Dnp
pH and temperature not specified in the publication
0.51
Abz-PRKQLATKAAR-dimethyl-K-SAK-Dnp
pH and temperature not specified in the publication
0.46
Abz-PRKQLATKAARKSAK-Dnp
pH and temperature not specified in the publication
0.01 - 0.5
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin
1.62 - 27.2
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
19.8
benzyloxycarbonyl-Lys-p-nitrophenyl ester
-
-
5.53 - 50
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
1.7 - 46
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
2.64
benzyloxycarbonyl-Pro-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
0.39 - 1.01
L-Phe-L-Arg-7-amido-4-methylcoumarin
0.89 - 1.07
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin
26.6
Leu-Trp-Met-Arg-Phe-Ala
-
-
33.9
leucine enkephalin
-
-
43.2
methionine enkephalin-Arg-Phe
-
-
12.8
N-carbobenzoxy-L-phenylalanine-L-arginine 7-amido-4-methylcoumarin
-
pH 5.5, 37°C
1.52
Pro-Phe-Arg-4-methylcoumarin 7-amide
-
-
2.48
tert-butyloxycarbonyl-Ala-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
1.67
tert-butyloxycarbonyl-Val-Leu-Lys-4-methylcoumarin 7-amide
-
-
1.17
tosyl-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
0.01
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
0.5
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L67Y/A205L
1.62
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
17.6
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
27.2
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L67Y/A205L
5.53
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
9.5
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
10
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
15.8
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
17
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
20
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
25.8
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
26
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
30
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
30
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
39
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
recombinant enzyme expressed Escherichia coli
50
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
recombinant enzyme expressed in mouse myeloma clls
1.7
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
2 - 3.7
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
5.4
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
6.2
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
9
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
mutant enzyme T223V/M274L/D275N/G277A/V278M
18
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
mutant enzyme T223V/DELTAE286-E289
20.5
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L67Y/A205L
30
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
mutant enzyme T223V/DELTAE286-N293
46
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
wild type enzyme
0.39
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.01 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25°C
0.43
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.02 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25°C
0.45
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.005 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25°C
0.52
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25°C
0.52
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.001 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25°C
1.01
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 37°C
0.89
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25°C
1.07
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0004
(2R,3R)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
0.0048
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0059
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0048
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0059
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0529
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
0.026
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
0.0101
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
0.0101
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
0.0187
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
0.0178
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]aziridine-2,3-dicarboxylic acid
-
-
0.0178
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
0.0153
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
0.0159
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
0.0064
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(R)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.000013
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(S)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0014
(2S,3S)-dibenzyl-1-[biotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
0.0042
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0042
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.004
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
0.0216
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
0.0147
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
0.0038
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0044
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.006
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-prolyl]-aziridine-2,3-dicarboxylate
-
-
0.0038
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0044
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0152
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
0.0166
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
0.0058
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0071
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-prolyl]aziridine-2,3-dicarboxylate
-
-
0.0058
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R+S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0064
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-pipecolyl]-aziridine-2,3-dicarboxylate
-
-
0.0158
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
0.0024
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0024
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0077
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
0.0079
(2S,3S+2R,3R)-dibenzyl-1-[desthiobiotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
0.0053
(E)N-[(S)1-[(S)2-cyano-1-pyrrolidinecarbonyl]-3-methylbutyl]-2,3-diphenylacrylamide
-
23°C, pH 6.0
0.023
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([2-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.002
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0023
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0025
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.012
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.011
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.013
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.014
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-3-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.013
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-4-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.013
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(thiophen-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.011
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[methyl(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.014
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(methylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.031
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(phenylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.016
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-([[4-([[(dimethylamino)methyl]sulfonyl]amino)phenyl]carbonyl]amino)-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.029
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([2-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0078
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-fluoro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0072
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.017
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([4-[(ethylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.016
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.011
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0078
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.014
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0059
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.011
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.015
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-(methylsulfamoyl)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0091
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-([[4-(1-methylethyl)-1,3-thiazol-2-yl]sulfonyl]amino)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.027
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-sulfamoylphenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.024
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methyl-1H-imidazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.015
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methylethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.015
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2,2,2-trifluoroethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0084
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2-methylphenyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.027
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0087
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methylpyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.017
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(5-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.01
1,4-anhydro-3,5,6-trideoxy-3-[[4-methyl-N-(thiophen-3-ylcarbonyl)-L-leucyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.00097
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0011
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.015
1,4-anhydro-3-[[(2S)-2-[([4-[(benzylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.021
1,4-anhydro-3-[[(2S)-2-[([4-[(butylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.012
1,4-anhydro-3-[[(2S)-2-[([4-[(cyclopropylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.023
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-chloropyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0085
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0068
1,4-anhydro-3-[[(2S)-2-[[(4-[[(3-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0079
1,4-anhydro-3-[[(2S)-2-[[(4-[[(4-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.064
1,4-anhydro-3-[[(2S)-2-[[(4-[[(cyclohexylmethyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.00923
3-(hydroxyimino)masticadienoic acid
-
at pH 5.5 and 37°C
0.002
3-(hydroxyimino)oleanolic acid
-
at pH 5.5 and 37°C
0.0195
3-epiursolic acid
-
at pH 5.5 and 37°C
0.00126
3-oxo-urs-12-en-28-oic acid
pH 6.5, 25°C
0.0095
3-[[(2S)-2-[([3-acetyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0091
3-[[(2S)-2-[[(4-[[(4-aminophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.00014
agathisflavone
pH 6.5, 25°C
0.00000057
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-naphthylen-2-yl)amide
-
-
0.0000017
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-phenyl-ethyl)amide
-
-
0.0026
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxo-3-(1,1':4',1''-terphenyl-4-yl)propan-2-yl]carbamate
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.023
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(2'-methylbiphenyl-4-yl)-1-oxopropan-2-yl]carbamate
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0025
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(3'-methylbiphenyl-4-yl)-1-oxopropan-2-yl]carbamate
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0017
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(4'-methylbiphenyl-4-yl)-1-oxopropan-2-yl]carbamate
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0018
benzyl [(2S)-3-(3'-aminobiphenyl-4-yl)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamate
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0017
benzyl [(2S)-3-(3'-chlorobiphenyl-4-yl)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamate
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0024
benzyl [(2S)-3-(biphenyl-4-yl)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamate
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.03
biphenyl-4-yl-acetylasparagine-D-Arg-Phe-Phe-NH2
pH 5.5, 25°C
0.00021
biphenyl-4-yl-acetylcysteine-D-Arg-Abu-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.0039
biphenyl-4-yl-acetylcysteine-D-Arg-Arg-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.081
biphenyl-4-yl-acetylcysteine-D-Arg-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.000021
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.00017
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-Phe-NH2
pH 5.5, 25°C
0.000067
biphenyl-4-yl-acetylcysteine-D-Arg-Trp-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.000045
biphenyl-4-yl-acetylcysteine-D-Arg-Tyr-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.00027
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Leu-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.00024
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Met-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.000019
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.00021
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(3-phenylpropyl)amide
pH 5.5, 25°C
0.0066
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(benzyl)amide
pH 5.5, 25°C
0.00007
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-Phe-NH2
pH 5.5, 25°C
0.0002
biphenyl-4-yl-acetylmethylcysteine-D-Orn-Phe-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.00093
biphenyl-4-yl-acetylmethylcysteine-Gly-Phe-Phe-NH2
pH 5.5, 25°C
0.00049
biphenyl-4-yl-acetylnorvaline-D-Arg-Phe-N-(2-phenylethyl)amide
pH 5.5, 25°C
0.07
biphenyl-4-yl-acetylserine-D-Arg-Phe-Phe-NH2
pH 5.5, 25°C
0.000023
biphenylacetyl-(N6-biphenylacetyl)-Lys-D-Arg-Tyr-N-phenylethyl
pH and temperature not specified in the publication
0.000511
biphenylacetyl-(N6-biphenylacetyl)Lys-D-Arg-Phe-N-phenylethyl
pH and temperature not specified in the publication
0.000019
biphenylacetyl-MCys-D-Arg-Phe-N-phenylethyl
pH and temperature not specified in the publication
0.0000026
cathepsin K propeptide
-
pH 5.5, room temperature
-
0.00000012
cathepsin L propeptide
-
pH 5.5, room temperature
-
0.00000046
cathepsin S propeptide
-
pH 5.5, room temperature
-
0.0000000073
chagasin
-
-
-
0.0000022
chagasin mutant deltaT31-T32
-
-
-
0.000000045
chagasin mutant P30A
-
-
-
0.0000000039
chagasin mutant T31A
-
-
-
0.0000000018
chagasin mutant T31A/T32A
-
-
-
0.0000000049
chagasin mutant T31S
-
-
-
0.0000000097
chagasin mutant T31V
-
-
-
0.0000000068
chagasin mutant T31Y
-
-
-
0.000000014
chagasin mutant T32A
-
-
-
0.000000032
chagasin mutant T32S
-
-
-
0.00000002
chagasin mutant T32V
-
-
-
0.0000000027
chagasin mutant T32Y
-
-
-
0.000000825
chagasin mutant W93A
-
-
-
0.00000005 - 0.00000021
cystatin A
-
0.00000005 - 0.00000046
cystatin B
-
0.00000008
cystatin C
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.00000281 - 0.0000065
cystatin D
-
0.00000019
cystatin E/M
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24°C
-
0.00000021 - 0.00000049
cystatin F
-
0.00000178
cystatin M/E
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.00000051
cystatin SA
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24°C
-
0.00000027
cystatin SN
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24°C
-
0.0000000072 - 0.0000000101
fragment p41 of major histocompatibility complex class II-associated invariant chain
-
0.0107
KAPR-acetyl-K-QLATKAARKSAPA
pH and temperature not specified in the publication
0.00502
KAPRKQLAT-acetyl-K-AARKSAPA
pH and temperature not specified in the publication
0.00455
KAPRKQLATKAAR-dimethyl-K-SAPA
pH and temperature not specified in the publication
0.0045
KAPRKQLATKAARKSAPA
pH and temperature not specified in the publication
0.05241
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25°C
0.02
N-(2,6-dimethylbenzoyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0027
N-(2-chloro-5-nitrobenzoyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0032
N-(3-phenylpropanoyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0043
N-(4-biphenylacetyl)-S-methylcysteine-(D)-Arg-Phe-beta-phenethylamide
-
wild type enzyme
0.0023
N-(4-bromobenzoyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.009
N-(biphenyl-4-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0078
N-(cyclopent-1-en-1-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.001
N-(naphthalen-2-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0068
N-(pentafluorobenzoyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0061
N-(piperidin-2-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0055
N-(pyridin-2-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.007
N-[(2R)-2-[(2-amino-2-oxoethyl)amino]-2-[[(benzyloxy)carbonyl]amino]acetyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.00089
N-[(2R)-2-[(3-aminopropyl)amino]-2-[[(benzyloxy)carbonyl]amino]acetyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.00039
N-[(2R)-2-[[(benzyloxy)carbonyl]amino]-2-(3a,7a-dihydro-1H-indol-3-ylamino)acetyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.00045
N-[(2R)-2-[[(benzyloxy)carbonyl]amino]-2-(propan-2-ylamino)acetyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.00074
N-[(2R)-2-[[(benzyloxy)carbonyl]amino]-2-[(2-carbamimidamidoethyl)amino]acetyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0046
N-[(4'-carboxy-2,2'-bipyridin-4-yl)carbonyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.005
N-[(6-aminopyridin-3-yl)carbonyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0031
N-[(benzyloxy)carbonyl]-3-(1H-indazol-1-yl)-L-alanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0042
N-[(benzyloxy)carbonyl]-3-(1H-indol-1-yl)-L-alanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.00012
N-[(benzyloxy)carbonyl]-4-(thiophen-2-yl)-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.014
N-[(benzyloxy)carbonyl]-L-phenylalanyl-3-(1H-imidazol-1-yl)-L-alaninamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.026
N-[(benzyloxy)carbonyl]-L-phenylalanyl-4-amino-L-phenylalaninamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.027
N-[(benzyloxy)carbonyl]-L-phenylalanyl-6-hydroxy-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.016
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-alaninamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.028
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-argininamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.014
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-leucinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0042
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.064
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-methioninamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0035
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-ornithinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.017
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-valinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0026
N-[(benzyloxy)carbonyl]-L-phenylalanyl-N6-methyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0014
N-[(benzyloxy)carbonyl]-L-tyrosyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0025
N-[3-(4-hydroxyphenyl)propanoyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0024
N-[3-(acetyloxy)benzoyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0026
N-[4-(acetyloxy)benzoyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.0029
N-[4-(dimethylamino)benzoyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.001
N-[4-(trifluoromethyl)benzoyl]-L-phenylalanyl-L-lysinamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.028
Nalpha-[(benzyloxy)carbonyl]-N-[(1R)-1,2-diamino-2-oxoethyl]-L-phenylalaninamide
-
100 mM phosphate buffer, pH 6.0, 2 mM EDTA, temperature not specified in the publication
0.00000043
naphthalene-2-carboxylic acid ((S)-2-naphthalen-2-yl-1-[(S)-3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]ethyl)amide
-
-
0.0000014
naphthoic-1-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
0.0095
ortho-aminobenzoic acid-LFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
at 37°C, in 0.1 M sodium acetate buffer, pH 5.5
0.005
ortho-aminobenzoic acid-VLFEKKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
at 37°C, in 0.1 M sodium acetate buffer, pH 5.5
0.0002
ortho-aminobenzoic acid-VLFEKKVYLQ-N-[2,4-dinitrophenyl]ethylenediamine
-
at 37°C, in 0.1 M sodium acetate buffer, pH 5.5
0.01
ortho-aminobenzoic acid-VLFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
at 37°C, in 0.1 M sodium acetate buffer, pH 5.5
0.00000000149 - 0.0000000101
p41-fragment-human
-
0.00000000722
p41-fragment-mouse
substrate: benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide, production rate of 7-amino-4-methylcoumarin measured, excitation and emission wavelengths of 370 and 460 nm, pseudo first order reaction conditions (inhibitor concentration at least 10-fold higher than enzyme concentration)
-
0.0000006
Phe-Tyr-(OBut)-COCHO
pH and temperature not specified in the publication
0.006
quercetin
pH 6.5, 25°C
0.000005
quinoline-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
0.0000082
quinoline-8-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
0.00013
RKLLW-NH2
-
pH 5.5, 37°C
0.0000007
testican-1
-
-
-
0.00073
tetrahydrorobustaflavone
pH 6.5, 25°C
0.00000014
thyroglobulin type-1 domain
-
0.1 M sodium acetate, 1 mM EDTA, 24°C
-
0.00000059
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24°C
additional information
additional information
-
0.00000005
cystatin A
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.00000021
cystatin A
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24°C
-
0.00000005
cystatin B
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.00000046
cystatin B
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24°C
-
0.00000281
cystatin D
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.0000065
cystatin D
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24°C
-
0.00000021
cystatin F
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24°C
-
0.00000049
cystatin F
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.0000000072
fragment p41 of major histocompatibility complex class II-associated invariant chain
pH 6.0, 25°C
-
0.0000000101
fragment p41 of major histocompatibility complex class II-associated invariant chain
pH 6.0, 25°C
-
0.00000000149
p41-fragment-human
substrate: benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide, production rate of 7-amino-4-methylcoumarin measured, excitation and emission wavelengths of 370 and 460 nm, pseudo first order reaction conditions (inhibitor concentration at least 10-fold higher than enzyme concentration)
-
0.00000000552
p41-fragment-human
wild-type, substrate: benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide, production rate of 7-amino-4-methylcoumarin measured, excitation and emission wavelengths of 370 and 460 nm, pseudo first order reaction conditions (inhibitor concentration at least 10-fold higher than enzyme concentration)
-
0.0000000101
p41-fragment-human
G139R mutant, substrate: benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide, production rate of 7-amino-4-methylcoumarin measured, excitation and emission wavelengths of 370 and 460 nm, pseudo first order reaction conditions (inhibitor concentration at least 10-fold higher than enzyme concentration)
-
additional information
additional information
inhibition kinetics
-
additional information
additional information
-
inhibition kinetics
-
additional information
additional information
inhibition kinetics of collagen with cathepsin L, overview
-
additional information
additional information
-
inhibition kinetics of collagen with cathepsin L, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0082
(13alpha,17alpha,20S,24Z)-3-hydroxylanosta-7,24-dien-26-oic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.0091
(13alpha,17alpha,20S,24Z)-3-oxolanosta-7,24-dien-26-oic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.01
(2-fluorobenzophenone) thiosemicarbazone
Homo sapiens
above, pH 6.0, 37°C
0.000574
(2E)-2-(6-bromo-1,1-dioxido-2,3-dihydro-4H-thiochromen-4-ylidene)hydrazinecarbothioamide
Homo sapiens
pH 6.0, 37°C
0.000152
(2E)-2-(6-bromo-2,3-dihydro-4H-thiochromen-4-ylidene)hydrazinecarbothioamide
Homo sapiens
pH 6.0, 37°C
0.000164
(2E)-2-(6-bromo-2,3-dihydroquinolin-4(1H)-ylidene)hydrazinecarbothioamide
Homo sapiens
pH 6.0, 37°C
0.000068
(2E)-2-(6-nitro-2,3-dihydro-4H-thiochromen-4-ylidene)hydrazinecarbothioamide
Homo sapiens
pH 6.0, 37°C
0.00246
(2E)-2-[(2-fluorophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000118
(2E)-2-[(3-bromophenyl)(3,4,5-trifluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000415
(2E)-2-[(3-bromophenyl)(3,5-dichlorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000594
(2E)-2-[(3-bromophenyl)(3,5-difluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000131
(2E)-2-[(3-bromophenyl)(3-chlorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00025
(2E)-2-[(3-bromophenyl)(3-fluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000224
(2E)-2-[(3-bromophenyl)(3-methylphenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.01
(2E)-2-[(3-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.000327
(2E)-2-[(3-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000796
(2E)-2-[(3-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00216
(2E)-2-[(3-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000465
(2E)-2-[(3-bromophenyl)[3-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000521
(2E)-2-[(3-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.01
(2E)-2-[(4-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00332
(2E)-2-[(4-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00457
(2E)-2-[(4-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.01
(2E)-2-[(4-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.01
(2E)-2-[6-(propan-2-yloxy)-2,3-dihydro-4H-thiochromen-4-ylidene]hydrazinecarbothioamide
Homo sapiens
above, pH 6.0, 37°C
0.000096
(2E)-2-[[3,5-bis(trifluoromethyl)phenyl](3-bromophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.5
(2E)-[(3E)-28-methoxy-28-oxours-12-en-3-ylidene]acetic acid
Homo sapiens
-
IC50 above 0.5 mM, at pH 5.5 and 37°C
0.0000019 - 0.00022
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
0.0026
(2Z)-2-[(2-bromophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.01
(2Z)-2-[(2-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.01
(2Z)-2-[(2-fluorophenyl)(phenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.000233
(2Z)-2-[(3-bromo-2-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000114
(2Z)-2-[(3-bromo-4-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000632
(2Z)-2-[(3-bromophenyl)(2,3,4,5-tetrafluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000838
(2Z)-2-[(3-bromophenyl)(2,3-difluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00061
(2Z)-2-[(3-bromophenyl)(2,6-difluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00161
(2Z)-2-[(3-bromophenyl)(2-chlorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000305
(2Z)-2-[(3-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.01
(2Z)-2-[(3-bromophenyl)(2-methylphenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00222
(2Z)-2-[(4-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000305
(3-bromo-2'-fluoro-3'-hydroxybenzophenone) thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.0001314
(3-bromo-3'-hydroxybenzophenone) thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.01
(3-hydroxybenzophenone) thiosemicarbazone
Homo sapiens
above, pH 6.0, 37°C
0.0097
(3E)-3-(carboxymethylidene)olean-12-en-28-oic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.0123
(3E)-3-(carboxymethylidene)urs-12-en-28-oic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.00222
(4-bromo-2'-fluoro-3'-hydroxybenzophenone) thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.000056
1,3,5-trisbenzoylbenzene thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.0000081
1,3-bis(2-fluorobenzoyl)-5-bromobenzene thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.01035
1,3-bis(3-bromobenzoyl)-5-bromobenzene thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.01
1,3-bis(3-bromobenzoyl)-5-hydroxybenzene thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.0000716
1,3-bis(3-hydroxybenzoyl)-5-bromobenzene thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.000654
1,3-bis(3-methylbenzoyl)benzene thisosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.01
1,3-bis(4-bromobenzoyl)benzene bis-thiosemicarbazone
Homo sapiens
above, pH 6.0, 37°C
0.001522
1,3-bis(4-bromobenzoyl)benzene thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.0000144
1,3-bis(4-fluorobenzoyl)benzene thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.00034
1,3-bis(4-hydroxybenzoyl)benzene thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.01
1,3-bis(4-isopropoxybenzoyl)benzene thiosemicarbazone
Homo sapiens
above, pH 6.0, 37°C
0.005117
1,3-bis(4-methoxybenzoyl)benzene thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.00045
1,3-dihydro-pyrrolo[3,4-b]quinoline-2-carbonitrile
Homo sapiens
-
IC50: 0.00045 mM
0.00001
1-cyano-3-azetidinyl cyclohexylmethyl ether
Homo sapiens
-
IC50: 0.00001 mM
0.00043
1-cyanoazetidine
Homo sapiens
-
IC50: 0.00043 mM
0.004
1-cyanopyrrolidine
Homo sapiens
-
IC50: 0.004 mM
0.00236 - 0.109
2,6-dimethoxy-4-[4-(4-phenoxyphenyl)-5-phenyl-1H-imidazol-2-yl]phenol
0.02 - 0.087
2,6-dimethoxy-4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
0.01293 - 0.0808
2-(1,3-benzodioxol-5-yl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
0.000007
2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarboxylate
Homo sapiens
-
-
0.00241 - 0.0863
2-(3,4-dimethoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
0.02 - 0.074
2-(4-methoxyphenyl)-4-[8-[2-(4-methoxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
0.01475 - 0.0818
2-(4-methoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
0.01932 - 0.0927
2-(acetylamino)-N-[4-(6-[[2-(acetylamino)benzoyl]amino]-1H-benzimidazol-2-yl)phenyl]benzamide
0.02 - 0.0402
2-(furan-2-yl)-4-[8-[2-(furan-2-yl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
0.0012
2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.0011
2-cyano-4-(cyclohexylamino)-N-(2-phenylethyl)pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00078
2-cyano-4-(cyclohexylmethoxy)-N-(2-phenylethyl)pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.000426
2-cyano-4-[(1,4-dioxaspiro[4.5]dec-8-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.0004
2-cyano-4-[(2-cyclopentylethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.002
2-cyano-4-[(cyclohexylmethyl)(methyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00001
2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-N-(2-phenylethyl)-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.0003
2-cyano-4-[[1-(2-hydroxyethyl)piperidin-4-yl]methoxy]-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00051
2-cyano-N-(1-methyl-4-phenylpiperidin-4-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00046
2-cyano-N-methyl-4-(piperidin-4-ylmethoxy)-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00036
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.000276
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[4.5]dec-8-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00139
2-cyano-N-methyl-4-[(spiro[3.5]non-7-ylmethyl)amino]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00012
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
0.00044
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00033
2-cyano-N-methyl-4-[[1-(1-methylethyl)piperidin-4-yl]methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.0007
2-cyano-N-[(1-methyl-4-phenylpiperidin-4-yl)methyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00048
2-cyano-N-[(1R)-2-pyridin-2-yl-1-(pyrrolidin-1-ylmethyl)ethyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00084
2-cyano-N-[5-[(1-methylpiperidin-4-yl)oxy]biphenyl-2-yl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.000044
2-furancarbonyl-leucyl-leucyl-leucinal
Rattus norvegicus
-
pH 5.0, 37°C
0.000007
2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarboxylic 3,4-dihydroquinoline-1(2H)-carboxylic anhydride
Homo sapiens
in 1 mM EDTA, 5 mM cysteine at pH 5.5
0.01
2-[bis(3-bromophenyl)methylidene]-N-ethylhydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.01
2-[bis(3-bromophenyl)methylidene]-N-phenylhydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00487
2-[bis(3-fluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
pH and temperature not specified in the publication
0.01
2-[bis(4-bromophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.01
2-[bis(4-fluorophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00893
2-[cyclohexyl(methyl)amino]-4H-3,1-benzothiazin-4-one
Homo sapiens
-
37°C, pH 6.0
0.00001
3-(benzyloxy)-1-cyanoazetidine
Homo sapiens
-
IC50: 0.00001 mM
0.0026
3-(hydroxyimino)masticadienoic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.0024
3-(hydroxyimino)oleanolic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.0000238
3-benzoylbenzhydrol thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.0065
3-epiursolic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.0072
3-hydroxyolean-12-en-28-oic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.0395
3-hydroxyurs-12-en-28-oic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.00378
3-oxo-urs-12-en-28-oic acid
Leishmania mexicana
pH 6.5, 25°C
0.0147
3-oxoolean-12-en-28-oic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.0083
3-oxours-12-en-28-oic acid
Homo sapiens
-
at pH 5.5 and 37°C
0.00015
3-[(benzyloxy)methyl]-1-cyanopyrrolidine
Homo sapiens
-
IC50: 0.00015 mM
0.00089 - 0.0847
4,4'-[methanediylbis(1H-benzimidazole-5,2-diyl)]dianiline
0.02 - 0.0865
4-(4-[8-[2-(4-carboxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)benzoic acid
0.00056 - 0.0621
4-(4-[8-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)phenol
0.00215 - 0.0834
4-amino-N-(4-[6-[(4-aminobenzoyl)amino]-1H-benzimidazol-2-yl]phenyl)benzamide
0.0025
4-[(1-acetylpiperidin-4-yl)methoxy]-2-cyano-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00178 - 0.0922
4-[(E)-benzylideneamino]-N-[4-[6-([4-[(E)-benzylideneamino]benzoyl]amino)-1H-benzimidazol-2-yl]phenyl]benzamide
0.00087
4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00981 - 0.08835
4-[4-(5,5-dioxidodibenzo[b,d]thiophen-2-yl)-5-phenyl-1H-imidazol-2-yl]-2,6-dimethoxyphenol
0.00047 - 0.00193
4-[5-(4-[[2-(4-aminophenyl)-1H-benzimidazol-6-yl]oxy]phenoxy)-1H-benzimidazol-2-yl]aniline
0.01749 - 0.0997
4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
0.02 - 0.0655
4-[8-(2,4-diphenyl-1H-imidazol-5-yl)dibenzo[b,d]furan-2-yl]-2,5-diphenyl-1H-imidazole)
0.00028
5-bromo-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00338 - 0.0981
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(2,4,5-trimethoxyphenyl)-1H-imidazole
0.01706 - 0.0888
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-1H-imidazole
0.000096
6-(4-chlorobenzyl)-7-(2,2-dimethylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00084
6-(4-chlorobenzyl)-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00032
6-(4-chlorobenzyl)-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00026
6-(4-chlorobenzyl)-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.000023
6-(4-chlorobenzyl)-7-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.000018
6-(4-chlorobenzyl)-7-(3,3-dimethylbutyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00037
6-(4-chlorobenzyl)-7-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00004
6-(4-chlorobenzyl)-7-[2-(3-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.000086
6-(4-chlorobenzyl)-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.0068
6-[[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
0.0052
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
0.0023
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
0.0062
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4,4-difluorocyclohexyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
0.00079
7-(2-cyclohexylethyl)-6-[(pyridin-2-yloxy)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT K employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.000057
acetyl-prolyl-leucyl-leucyl-leucinal
Rattus norvegicus
-
pH 5.0, 37°C
0.000019
acetyl-prolyl-prolyl-leucyl-leucyl-leucinal
Rattus norvegicus
-
pH 5.0, 37°C
0.00043
agathisflavone
Leishmania mexicana
pH 6.5, 25°C
0.01
benzophenone thiosemicarbazone
Homo sapiens
above, pH 6.0, 37°C
0.0000099
benzoylbenzophenone thiosemicarbazone
Homo sapiens
pH 6.0, 37°C
0.000054
benzyl 1-cyano-3-pyrrolidinylcarbamate
Homo sapiens
-
IC50: 0.000054 mM
0.000163
benzyloxycarbonyl-leucyl-leucyl-leucinal
Rattus norvegicus
-
pH 5.0, 37°C
0.0011 - 0.0972
bis[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methanone
0.000056
cathepsin L inhibitor 1
Homo sapiens
thiocarbazate cathepsin L inhibitor, 20 mM sodium acetate, 1 mM EDTA, 5 mM cysteine at pH 5.5
0.000056
CID 16725315
Homo sapiens
-
pH and temperature not specified in the publication
0.0000069
CID 23631927
Homo sapiens
-
pH and temperature not specified in the publication
0.1
diethyl-cyanamide
Homo sapiens
-
IC50 is above 0.1 mM
0.00003
E-64
Homo sapiens
-
at pH 5.5 and 37°C
0.00002
isonicotinyl-leucyl-leucyl-leucinal
Rattus norvegicus
-
pH 5.0, 37°C
0.1
L-3-trans-propylcarbamoyloxirane-2-carbonyl-L-isoleucyl-L-proline
Trypanosoma brucei
-
IC50 above 0.1 mM, at pH 5.0 and 22°C
0.0008
LFLTR-NH2
Homo sapiens
-
IC50: 0.0008 mM
0.0005
LLLTR-NH2
Homo sapiens
-
IC50: 0.0005 mM
0.25
methyl (13alpha,17alpha,20S,24Z)-3-hydroxylanosta-7,24-dien-26-oate
Homo sapiens
-
IC50 above 0.25 mM, at pH 5.5 and 37°C
0.5
methyl (3Z,13alpha,17alpha,20S,24Z)-3-(hydroxyimino)lanosta-7,24-dien-26-oate
Homo sapiens
-
IC50 above 0.5 mM, at pH 5.5 and 37°C
0.0386
methyl 5-acetyloxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
Homo sapiens
-
pH 5.5, 22°C
0.0616
methyl 5-hydroxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
Homo sapiens
-
pH 5.5, 22°C
0.000048
morpholinylsuccinyl-leucyl-leucyl-leucinal
Rattus norvegicus
-
pH 5.0, 37°C
0.00175
N-(1-cyano-3-pyrrolidinyl)benzamide
Homo sapiens
-
IC50: 0.00175 mM
0.00008
N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide
Homo sapiens
-
IC50: 0.00008 mM
0.00085
N-(1-cyano-3-pyrrolidinyl)[1,1'-biphenyl]-4-carboxamide
Homo sapiens
-
IC50: 0.00085 mM
0.00018
N-(4-benzyl-1-methylpiperidin-4-yl)-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.000064
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.0001
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)oxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00027
N-benzyl-2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.01
N-benzyl-2-[bis(3-bromophenyl)methylidene]hydrazinecarbothioamide
Homo sapiens
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.023
N-[(1-cyano-2-pyrrolidinyl)methyl]benzamide
Homo sapiens
-
IC50: 0.023 mM
0.0115
N-[(1-cyano-2-pyrrolidinyl)methyl]benzenesulfonamide
Homo sapiens
-
IC50: 0.0115 mM
0.00065
N-[(1-cyano-3-azetidinyl)methyl]benzamide
Homo sapiens
-
IC50: 0.00065 mM
0.00005
N-[(1-cyano-3-azetidinyl)methyl]benzenesulfonamide
Homo sapiens
-
IC50: 0.00005 mM
0.000006
N-[(1-cyano-3-azetidinyl)methyl]cyclohexanecarboxamide
Homo sapiens
-
IC50: 0.000006 mM
0.00035
N-[(1-cyano-3-pyrrolidinyl)methyl]benzenesulfonamide
Homo sapiens
-
IC50: 0.00035 mM
0.00015
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00084
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylpropyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.0015
N-[(1S)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00304 - 0.0625
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,2-diphenylacetamide
0.00283 - 0.0862
N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide
0.000027
nicotinyl-leucyl-leucyl-leucinal
Rattus norvegicus
-
pH 5.0, 37°C
0.01803
quercetin
Leishmania mexicana
pH 6.5, 25°C
0.0006
RKLLW-NH2
Homo sapiens
-
IC50: 0.0006 mM
0.014
RKLWD-NH2
Homo sapiens
-
IC50: 0.014 mM
0.0008
RKLWL-NH2
Homo sapiens
-
IC50: 0.0008 mM
0.00011
S-(2-oxo-1-phenylpyrrolidin-3-yl) 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
Homo sapiens
-
-
0.000041
S-[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
Homo sapiens
-
-
0.000001 - 0.000056
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
0.000115
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoyl]hydrazinecarbothioate
Homo sapiens
-
-
0.033
S-{2-[(2-ethylphenyl)amino]-2-oxoethyl} 2-[(2R)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
Homo sapiens
thiocarbazate cathepsin L inhibitor, 1 mM EDTA, 5 mM cysteine at pH 5.5
0.0022
tetrahydrorobustaflavone
Leishmania mexicana
pH 6.5, 25°C
additional information
(3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetic acid
0.0000019
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
Rattus norvegicus
-
-
0.00022
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
Trypanosoma brucei
-
at pH 5.0 and 22°C
0.00236
2,6-dimethoxy-4-[4-(4-phenoxyphenyl)-5-phenyl-1H-imidazol-2-yl]phenol
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.02
2,6-dimethoxy-4-[4-(4-phenoxyphenyl)-5-phenyl-1H-imidazol-2-yl]phenol
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.109
2,6-dimethoxy-4-[4-(4-phenoxyphenyl)-5-phenyl-1H-imidazol-2-yl]phenol
Homo sapiens
pH 7.4, 37°C
0.02
2,6-dimethoxy-4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.02
2,6-dimethoxy-4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.087
2,6-dimethoxy-4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
Homo sapiens
pH 7.4, 37°C
0.01293
2-(1,3-benzodioxol-5-yl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Trypanosoma brucei brucei
pH 7.4, 37°C
0.02
2-(1,3-benzodioxol-5-yl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.0808
2-(1,3-benzodioxol-5-yl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Homo sapiens
pH 7.4, 37°C
0.00241
2-(3,4-dimethoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.02002
2-(3,4-dimethoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Trypanosoma brucei brucei
pH 7.4, 37°C
0.0863
2-(3,4-dimethoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Homo sapiens
pH 7.4, 37°C
0.02
2-(4-methoxyphenyl)-4-[8-[2-(4-methoxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.02
2-(4-methoxyphenyl)-4-[8-[2-(4-methoxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.074
2-(4-methoxyphenyl)-4-[8-[2-(4-methoxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
Homo sapiens
pH 7.4, 37°C
0.01475
2-(4-methoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Trypanosoma brucei brucei
pH 7.4, 37°C
0.02
2-(4-methoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.0818
2-(4-methoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Homo sapiens
pH 7.4, 37°C
0.01932
2-(acetylamino)-N-[4-(6-[[2-(acetylamino)benzoyl]amino]-1H-benzimidazol-2-yl)phenyl]benzamide
Trypanosoma brucei brucei
pH 7.4, 37°C
0.02
2-(acetylamino)-N-[4-(6-[[2-(acetylamino)benzoyl]amino]-1H-benzimidazol-2-yl)phenyl]benzamide
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.0927
2-(acetylamino)-N-[4-(6-[[2-(acetylamino)benzoyl]amino]-1H-benzimidazol-2-yl)phenyl]benzamide
Homo sapiens
pH 7.4, 37°C
0.02
2-(furan-2-yl)-4-[8-[2-(furan-2-yl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.02
2-(furan-2-yl)-4-[8-[2-(furan-2-yl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.0402
2-(furan-2-yl)-4-[8-[2-(furan-2-yl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
Homo sapiens
pH 7.4, 37°C
0.00012
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00012
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00089
4,4'-[methanediylbis(1H-benzimidazole-5,2-diyl)]dianiline
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.0058
4,4'-[methanediylbis(1H-benzimidazole-5,2-diyl)]dianiline
Trypanosoma brucei brucei
pH 7.4, 37°C
0.0847
4,4'-[methanediylbis(1H-benzimidazole-5,2-diyl)]dianiline
Homo sapiens
pH 7.4, 37°C
0.02
4-(4-[8-[2-(4-carboxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)benzoic acid
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.02
4-(4-[8-[2-(4-carboxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)benzoic acid
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.0865
4-(4-[8-[2-(4-carboxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.00056
4-(4-[8-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)phenol
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.01179
4-(4-[8-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)phenol
Trypanosoma brucei brucei
pH 7.4, 37°C
0.0621
4-(4-[8-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)phenol
Homo sapiens
pH 7.4, 37°C
0.00215
4-amino-N-(4-[6-[(4-aminobenzoyl)amino]-1H-benzimidazol-2-yl]phenyl)benzamide
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.02
4-amino-N-(4-[6-[(4-aminobenzoyl)amino]-1H-benzimidazol-2-yl]phenyl)benzamide
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.0834
4-amino-N-(4-[6-[(4-aminobenzoyl)amino]-1H-benzimidazol-2-yl]phenyl)benzamide
Homo sapiens
pH 7.4, 37°C
0.00178
4-[(E)-benzylideneamino]-N-[4-[6-([4-[(E)-benzylideneamino]benzoyl]amino)-1H-benzimidazol-2-yl]phenyl]benzamide
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.02
4-[(E)-benzylideneamino]-N-[4-[6-([4-[(E)-benzylideneamino]benzoyl]amino)-1H-benzimidazol-2-yl]phenyl]benzamide
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.0922
4-[(E)-benzylideneamino]-N-[4-[6-([4-[(E)-benzylideneamino]benzoyl]amino)-1H-benzimidazol-2-yl]phenyl]benzamide
Homo sapiens
pH 7.4, 37°C
0.00981
4-[4-(5,5-dioxidodibenzo[b,d]thiophen-2-yl)-5-phenyl-1H-imidazol-2-yl]-2,6-dimethoxyphenol
Trypanosoma brucei brucei
pH 7.4, 37°C
0.02
4-[4-(5,5-dioxidodibenzo[b,d]thiophen-2-yl)-5-phenyl-1H-imidazol-2-yl]-2,6-dimethoxyphenol
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.08835
4-[4-(5,5-dioxidodibenzo[b,d]thiophen-2-yl)-5-phenyl-1H-imidazol-2-yl]-2,6-dimethoxyphenol
Homo sapiens
pH 7.4, 37°C
0.00047
4-[5-(4-[[2-(4-aminophenyl)-1H-benzimidazol-6-yl]oxy]phenoxy)-1H-benzimidazol-2-yl]aniline
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.00193
4-[5-(4-[[2-(4-aminophenyl)-1H-benzimidazol-6-yl]oxy]phenoxy)-1H-benzimidazol-2-yl]aniline
Trypanosoma brucei brucei
pH 7.4, 37°C
0.01749
4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
Trypanosoma brucei brucei
pH 7.4, 37°C
0.02
4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.0997
4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
Homo sapiens
pH 7.4, 37°C
0.02
4-[8-(2,4-diphenyl-1H-imidazol-5-yl)dibenzo[b,d]furan-2-yl]-2,5-diphenyl-1H-imidazole)
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.02
4-[8-(2,4-diphenyl-1H-imidazol-5-yl)dibenzo[b,d]furan-2-yl]-2,5-diphenyl-1H-imidazole)
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.0655
4-[8-(2,4-diphenyl-1H-imidazol-5-yl)dibenzo[b,d]furan-2-yl]-2,5-diphenyl-1H-imidazole)
Homo sapiens
pH 7.4, 37°C
0.00338
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(2,4,5-trimethoxyphenyl)-1H-imidazole
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.01831
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(2,4,5-trimethoxyphenyl)-1H-imidazole
Trypanosoma brucei brucei
pH 7.4, 37°C
0.0981
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(2,4,5-trimethoxyphenyl)-1H-imidazole
Homo sapiens
pH 7.4, 37°C
0.01706
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-1H-imidazole
Trypanosoma brucei brucei
pH 7.4, 37°C
0.02
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-1H-imidazole
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.0888
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-1H-imidazole
Homo sapiens
pH 7.4, 37°C
0.0011
bis[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methanone
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.02
bis[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methanone
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.0972
bis[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methanone
Homo sapiens
pH 7.4, 37°C
0.00304
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,2-diphenylacetamide
Trypanosoma brucei rhodesiense
pH 5.5, 25°C
0.02
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,2-diphenylacetamide
Trypanosoma brucei brucei
above, pH 7.4, 37°C
0.0625
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,2-diphenylacetamide
Homo sapiens
pH 7.4, 37°C
0.00283
N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide
Trypanosoma brucei brucei
pH 7.4, 37°C
0.02
N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide
Trypanosoma brucei rhodesiense
above, pH 5.5, 25°C
0.0862
N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide
Homo sapiens
pH 7.4, 37°C
0.000001
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
Homo sapiens
-
pH 5.5, preincubation with enzyme 4 h before substrate addition
0.0000075
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
Homo sapiens
-
pH 5.5, preincubation with enzyme 1 h before substrate addition
0.000056
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
Homo sapiens
-
-
0.000056
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
Homo sapiens
-
pH 5.5
additional information
(3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetic acid
Homo sapiens
-
KI value is above 5 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
2-cyano-4-[(6,8-dioxaspiro[3.5]non-7-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
Homo sapiens
IC50 is above 0.001 mM, determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
2-cyano-4-[(cyclohexylmethyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
Homo sapiens
IC50 is above 0.002 mM, inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
2-cyano-4-[[(4,4-difluorocyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
Homo sapiens
IC50 is above 0.003 mM, inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
2-cyano-4-[[(4,4-dimethylcyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
Homo sapiens
IC50 is above 0.003 mM inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
2-cyano-N-(2-phenylethyl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
IC50 is above 0.003 mM inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
2-cyano-N-(4,5-dimethoxybiphenyl-2-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
Homo sapiens
IC50 is above 0.003 mM inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzoic acid
Homo sapiens
-
KI value is above 2 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-(4-chlorobenzyl)-7-(2-cyclooctylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-(4-chlorobenzyl)-7-(2-piperidin-1-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-(4-chlorobenzyl)-7-(3-cyclohexylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-(4-chlorobenzyl)-7-(4,4-dimethylpentyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-[[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-[[4-(1-acetylpiperidin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 4 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-[[4-(4-acetyl-1,4-diazepan-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
IC50 is above 1 M, with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Rattus norvegicus
-
IC50 is above 0.01 mM, Z-Phe-Arg-7-amino-4-methylcumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)-3-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
IC50 is above 1 M, with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
IC50 is above 2 M, with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Rattus norvegicus
-
IC50 is above 0.01 mM, Z-Phe-Arg-7-amino-4-methylcumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 4 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4,4-difluorocyclohexyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Rattus norvegicus
-
IC50 is above 0.01 mM, Z-Phe-Arg-7-amino-4-methylcumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
IC50 is above 1 M, with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
7-(2-cyclohexylethyl)-6-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
7-(2-cyclohexylethyl)-6-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
7-(2-cyclohexylethyl)-6-(phenoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
7-(2-cyclohexylethyl)-6-[(phenylamino)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
7-(2-cyclohexylethyl)-6-[(pyridin-2-ylsulfanyl)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
7-(2-cyclohexylethyl)-6-[[methyl(phenyl)amino]methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
CLIK-148
Homo sapiens
IC50 value is below 0.0001 mM, in 1 mM EDTA, 5 mM cysteine at pH 5.5
additional information
N-(4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetamide
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
N-(4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)propanamide
Homo sapiens
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.